Virtual Experience

Home , Woodhull Medical Center

Program Guide

ACAAI 2020 ANNUAL SCIENTIFIC MEETING The Changing Practice Landscape RISING to the CHALLENGE

Nov. 13-15 VIRTUAL EXPERIENCE

#ACAAI20

LIVE RECORDED RECORDED+ 1 COMING SOON

Visit our virtual booth at the ACAAI 2020 Annual Scientific Meeting.

Want to receive future updates on ORLADEYOTM (berotralstat)?

LIVE RECORDED RECORDED+ 2 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

The Changing Practice Landscape Nov. 13-15 RISING to the VIRTUAL CHALLENGE EXPERIENCE

2019 – 2020 Officers and Board of Regents

J. Allen Meadows, MD, FACAAI Gailen D. Marshall, Jr., MD, PhD, FACAAI. . . 2020 President...... 2020 Mamta Reddy, MD, MBOE, FACAAI...... 2020 Todd A. Mahr, MD, FACAAI Gary C. Steven, MD, PhD, FACAAI...... 2020 Immediate Past President ...... 2020 Kelly M. Maples, MD, FACAAI...... 2021 Luz S. Fonacier, MD, FACAAI President-elect...... 2020 Melinda M. Rathkopf, MD, FACAAI...... 2021 Mark Corbett, MD, FACAAI Michael R. Rupp, MD, FACAAI...... 2021 Vice President ...... 2020 Kevin R. Murphy, MD, FACAAI...... 2022 Kathleen R. May, MD, FACAAI John Seyerle, MD, FACAAI...... 2022 Treasurer...... 2020 J. Wesley Sublett, MD, MPH, FACAAI . . . . .2022 Bradley E. Chipps, MD, FACAAI Past Immediate Past President...... 2020

FIT Representatives: Miriam Samstein, MD, PhD (2020), and Timothy Chow, MD (2021) Advocacy Council Chair: James M. Tracy, DO, FACAAI (2021) Executive Medical Director: Michael S. Blaiss, MD, FACAAI Annals Editor-in-chief: Gailen D. Marshall, Jr., MD, PhD, FACAAI (2021) Alliance President: Cheryl Carr (2020)

3 ACAAI Premier Partners

The American College of Allergy, Asthma and Immunology recognizes the indispensable role that health care companies play in furthering the mission of the College. ACAAI would like to thank the following companies for their generous support of this year’s Annual Meeting. Diamond $500,000 and above Sanofi Genzyme and Regeneron Platinum $300,000 – $499,999 AstraZeneca Gold $100,000 – $299,999 Aimmune Therapeutics DBV Technologies Genentech GSK Merck Pfizer, Inc. Takeda Pharmaceutical Company Limited Silver $50,000 – $99,999 abbvie ALK kaléo Pharming Group NV Teva Pharmaceuticals, Inc.

Other Contributors Amgen • AstraZeneca and Amgen • BioCryst Blueprint Medicines • CSL Behring • Fresenius Kabi USA, LLC Novartis Pharmaceuticals Corporation • Optinose Purina Institute • Stallergenes Greer

4 Table of Contents

ACAAI Premier Partners ...... 4 Evaluation and Credit Claiming ...... 22 2020 Program Committee ...... 5 Schedule at a Glance ...... 23 Message From the Program Chair ...... 7 Named Lectures ...... 27 2020 Award Winners ...... 9 Friday, November 13 ...... 28 Corporate Supporters ...... 11 Saturday, November 14 ...... 37 Commercial Supporters ...... 12 Sunday, November 15 ...... 50 Special Announcements ...... 15 E-posters ...... 63 SPARK Program ...... 18 Industry Programs ...... 64 Education Information ...... 19 Exhibits ...... 71 Maintenance of Certification ...... 21

2020 Program Committees

2020 Annual Meeting Program Committee David R. Stukus, MD, Chair Brian T. Kelly, MD, MA, Vice-chair Michael S. Blaiss, MD • Mark L. Corbett, MD • Luz S. Fonacier, MD • Sandra M. Gawchik, DO Matthew Greenhawt, MD, MBA, MSc • Jeremy S. Katcher, MD • Lisa J. Kobrynski, MD, MPH J. Allen Meadows, MD • Mervat Nassef, MD • Maeve E. O’Connor, MD • John J. Oppenheimer, MD Purvi S. Parikh, MD • Melinda M. Rathkopf, MD • Melanie A. Ruffner, MD, PhD • Michael R. Rupp, MD Jodi A. Shroba, MSN, APRN, CPNP • J. Wesley Sublett, MD, MPH • Miriam Samstein, MD, PhD, FIT Representative Literature Review Liaison: David Khan, MD

2020 Allied Health Committee Jodi A. Shroba, MSN, APRN, CPNP, Chair Abby L. Allen, RN, NP, Vice-chair Michelle R. Dickens, NP • Tara Doran, RN, BSN, MHA • Raquel Z. Durban, MS, RD, CSP, LDN Maureen George, PhD, RN, AE-C • Tamara Hubbard, MA, LCPC • Ashlee Law, PA-C • Megan O. Lewis, MSN, RN, CPNP Amanda L. Michaud, PA-C • Helen M. Murphy, RRT, AE-C • Ms. Iris Torres, RMA

2020 Practice Management Committee Kevin P. McGrath, MD, Chair Thomas J. Derrico, Vice-chair Melinda M. Rathkopf, MD, Vice-chair Stanley M. Fineman, MD, MBA • Charlie F. Furr, Jr. • Jennifer Kuehn, CPC • Alnoor A. Malick, MD Scott McCutcheon, MHA • Mohsen Nasir, MD • Jean L. Owen, MBA, CT(ASCP) • M. Razi Rafeeq, MD Paul A. Shapero, MD • Mike Tankersley, MD, MBA • John W. Tole, DO • James M. Tracy, DO • Kay Tyler, BS, BA, MBA

5 The Journey Towards Controlled Asthma: Shifting the Treatment Paradigm Description: A goal of asthma treatment is to achieve and maintain asthma control; however, uncontrolled asthma continues to be a burden for patients, their care team, and the healthcare system. There is a need for providers and patients to share decision making while continuously evaluating treatment options that will maximize lung function, minimize symptoms and risk of exacerbations while decreasing the risk of adverse events. Medical experts will provide insight into the challenges of coping with uncontrolled asthma, review the current treatment paradigms, and identify ways to customize management of uncontrolled asthma by pairing the right medications with the right patients.

Speakers: John Oppenheimer, MD Angela Hogan, MD

Saturday, November 14, 2020 6:15 pm - 7:15 pm CST

An Industry Sponsored Program. Sponsored by GSK.

To access this industry program you must be registered for the virtual 2020 ACAAI Annual Scientific Meeting. All programs can be accessed via the main auditorium of the virtual meeting platform.

This program is limited to Health Care Professionals (HCP) only. Some state laws prohibit manufacturers from providing meals or transfers of value to HCPs. GSK complies with all state and federal laws including transparent reporting and disclosure of payments and transfers of value to HCPs.This is a non-CME event and does not qualify for CME, CE, or MOC credit. This event is not part of the official conference sessions.

The Industry Program content and views expressed therein do not necessarily reflect the views, policies or position of the American College of Allergy, Asthma and Immunology.

On behalf of the Program • Research? We’ve got it virtually. View e-posters at Committee, welcome to the your convenience. They are available on demand College’s 2020 virtual Annual starting Friday at 9:30 am CST. We’ve added Meeting. When I walked out of our a new feature this year, and e-posters will be “final” planning meeting in late accompanied by recorded author presentations! February, I had no idea the extent • Don’t miss the FIT Bowl! You didn’t think we were to which our world was about to going to let the Fellows-in-Training off the hook, change. Alas, we David Stukus, MD, FACAAI did you? An Annual Meeting tradition, join us for a were fortunate Chair of the Annual Meeting virtual spin on this knowledge competition for FIT Program Committee to have time to teams on Saturday at 5:15 pm CST. regroup and we are very proud to be able to bring you a meeting • Yes, there will be an exhibit hall! No meeting filled with outstanding education, research and would be complete without our industry partners. networking. We’ll give you the practical takeaways You’ll be able to chat with industry representatives you need to care for patients and advance your and view their interactive exhibits starting on practice, no matter your career stage or clinical Friday at 9:30 am CST. Don’t forget to collect your setting. tokens at participating booths to be eligible to win prizes! Our session topics live up to this year’s theme, the Changing Practice Landscape – Rising to the • Visit the College booth in the virtual exhibit hall Challenge (our theme was actually chosen 18 to see how the College is working for you. We’ll months ago…who knew?). Here are some highlights be on hand during exhibit hours to greet you and so you can maximize your experience: answer your College questions. • Expert tips at the Presidential Plenary. We’re • Virtual social experiences round out the meeting. excited to have Mr. Harold Miller, President and In addition to the FIT Bowl, visit the Networking CEO of the Center for Healthcare Quality and Lounge to connect with peers. Payment Reform, presenting “Why ‘Value-based Keep the momentum going during the meeting! Payment’ Isn’t Working – And How Physicians Can Tweet the best pearls and tips you’re learning from Fix It” during the Presidential Plenary on Friday at each session, and use #ACAAI20 in your tweets. 8:00 am CST. Follow Facebook and Twitter for breaking Annual • New, Friday LIVE sessions. Don’t miss Friday Meeting news. afternoon’s sessions on COVID-19 and disparities. I hope you enjoy the one-of-a-kind experience at These were developed to specifically address this year’s virtual Annual Meeting. We’re looking timely topics important to all of us. forward to hopefully meeting in person next year in • “Not on Thursday” program. Two topics are New Orleans. Please feel free to give us feedback covered in depth: cough and biologics. Learn during and after the meeting via the evaluations or about testing, diagnosis and treatment of cough at the help desk. I assure you that your comments and optimizing biologics for allergic conditions. are extremely important to us as we plan future These sessions take place on Saturday. meetings. While we can’t be together in person, we can still be together throughout this wonderful • Tune in to your favorites. Plan to attend favorites weekend. like the Annual Literature Review, CAP Review and oral abstract sessions. Nonmember attendees must preregister for the Literature Review.

LIVE RECORDED RECORDED+ 7 Investigating the Role of Eosinophils in Health, Airway Disease, and Hypereosinophilic Disorders

Program Description: Eosinophils are now well recognized as major players in immune-mediated disorders. This program will review the immunomodulatory role of eosinophils in health and disease as well as their involvement in various disorders, including severe asthma (and potential co-morbidities) and hypereosinophilic disorders. The importance of biomarkers in the evaluation of eosinophilic disorders will be highlighted.

Chair: Speakers:

Charlene Prazma, PhD Steven J Ackerman, PhD Jonathan Corren, MD Princess Ogbogu, MD

Friday, November 13, 2020 11:35 am - 12:30 pm CST

Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease

Program Description: Hypereosinophilic syndrome (HES) is a rare and debilitating multi-system disorder characterized by elevated eosinophil levels in blood and/or tissues with organ damage/dysfunction that occurs without evidence of secondary causes of hypereosinophilia. Multiple organ involvement results in highly variable clinical manifestations. This brief presentation will provide a summary of current understanding.

Speaker: Saturday, November 14, 2020 David Bernstein, MD 2:35 - 3:00 pm CST

An Industry Sponsored Program. Sponsored by GSK.

To access this industry program you must be registered for the virtual 2020 ACAAI Annual Scientific Meeting. All programs can be accessed via the main auditorium of the virtual meeting platform.

This program is limited to Health Care Professionals (HCP) only. Some state laws prohibit manufacturers from providing meals or transfers of value to HCPs. GSK complies with all state and federal laws including transparent reporting and disclosure of payments and transfers of value to HCPs. This is a non-CME event and does not qualify for CME, CE, or MOC credit. This event is not part of the official conference sessions.

The Industry Program Content and views expressed therein do not necessarily reflect the views, policies, or position of the American College of Allergy, Asthma and Immunology.

The College is proud to honor the following individuals for their service to the College and the specialty of allergy/ immunology. All awards will be presented during the ACAAI Business Meeting at 4:30 pm CST on Saturday.

GOLD HEADED CANE AWARD Distinguished Fellow Award

Stanley M. Fineman, MD, MBA, FACAAI Michael R. Nelson, MD, PhD, FACAAI Marietta, Georgia Olney, Maryland

Distinguished Service Awards

Travis A. Miller, MD, James M. Tracy, DO, Susan L. Grupe FACAAI FACAAI ACAAI Director Roseville, California Papillion, Nebraska of Advocacy Administration Barrington, Illinois

International Distinguished Woman in Executive Medical Fellow Award Allergy Award Director Award

Michael Levin, MD, Mariana C. Castells, Jennifer Pfeifer, MBA, PhD, FACAAI MD, PhD, FACAAI CMPE Rondebosch, Boston, Massachusetts ACAAI Practice South Africa Management Manager Northbrook, Illinois

Clemens von Pirquet Awards

First Place Second Place Third Place Jose Rojas Camayo, Lily Li, MD Deepti Deshpande, MD Brigham and MD University of Texas Women’s Hospital Columbia University Medical Branch

9 THIS IS REAL LIFE.

NUCALA Autoinjector

Trademarks owned or licensed by GSK. ©2020 GSK or licensor. MPLJRNA200007 September 2020 See for yourself at Produced in USA. RealLifeNUCALA.com Real patient compensated by GSK for his time. Corporate Supporters

ACAAI appreciates the following promotional contributions from its corporate supporters. abbvie Fresenius Kabi USA, LLC Supporter of the ACAAI Corporate Council. Supporter of a non-CME webinar on “HAE – Looking Into the Future”…and a broadcast message. Aimmune Therapeutics Supporter of the ACAAI Corporate Council…banner Genentech advertisement in the Help Desk…and an Industry Supporter of the ACAAI Corporate Council. Program presentation. GSK ALK Supporter of the ACAAI Corporate Council…two slide Supporter of the ACAAI Corporate Council…Find decks on “The Burden of Uncontrolled Asthma and an Allergist widget…and a non-CME webinar on the Role of LAMA in the Treatment of Asthma”…four “Operationalize Penicillin Allergy Testing.” Industry Programs presentations…Twitter content… two broadcast messages…banner advertisement in Amgen the Help Desk…and three advertisements in the final Supporter of the ACAAI Corporate Council. program guide. AstraZeneca and Amgen kaléo Supporter of an Industry Program presentation. Supporter of the ACAAI Corporate Council…College Insider…and an Industry Program presentation. AstraZeneca Supporter of the ACAAI Corporate Council…the Merck Leadership Summit…Allergy & Asthma Awareness Supporter of a Podcast Series on “Cough.” Toolkit…National Asthma & Allergy Awareness Month Toolkit…a non-CME webinar on “Asthma and Racial Novartis Pharmaceuticals Disparities – How Can Allergists Improve Outcomes”… Corporation three Industry Program presentations…Twitter content… Supporter of the ACAAI Corporate Council…and an banner advertisements in the Lobby…three broadcast Industry Program presentation. messages…and two pre-meeting email banner advertisements. Optinose BioCryst Supporter of the ACAAI Corporate Council. Supporter of an advertisement in the final program Pfizer, Inc. guide…Networking Lounge…banner advertisement Supporter of the ACAAI Corporate Council…“Reducing in the Help Desk…and a pre-meeting email banner Disparities in Atopic Dermatitis Education” Campaign… advertisement. two Industry Program presentations…two broadcast Blueprint Medicines messages…and a banner advertisement in the Resource Center. Supporter of an Industry Program presentation. Pharming Group NV DBV Technologies Supporter of the ACAAI Corporate Council…and a Supporter of the ACAAI Corporate Council …FIT Bowl… banner advertisement in the Lobby. and an Industry Program presentation.

Continues next page

11 Corporate Supporters (continued)

Purina Institute Stallergenes Greer Supporter of an Industry Program presentation. Supporter of the ACAAI Corporate Council. Sanofi Genzyme and Regeneron Takeda Pharmaceutical Company Supporter of the ACAAI Corporate Council…three Limited Industry Program presentations…Annual Meeting Supporter of the ACAAI Corporate Council… daily e-newsletter…e-posters…Twitter content… two Industry Program presentations…Twitter pre-meeting email banner advertisement…Find an content…banner advertisements in the Lobby and Allergist locator…AllergyWatch...the ACAAI Racial Resource Center…three pre-meeting email banner Disparities Resource Center…non-CME webinar on advertisements…and three broadcast messages. “Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)” …CRSwNP Educational Tool for Allergists Patient Teva Pharmaceuticals, Inc. Education Guide…CRSwNP Shared Decision-making Supporter of an Industry Program presentation…and a Toolkit…CRSwNP Patient Success Video and Digital non-CME webinar on “The Past, Present and Future of Ad Campaign…Severe Asthma Patient Success Video Asthma Monitoring Devices.” and Digital Ad Campaign…Atopic Dermatitis Patient Success Video and Digital Ad Campaign…Asthma page on ACAAI website…Eczema page on ACAAI website …Adult Asthma Shared Decision-Making Online Tool Redesign…Practice Management Resource Video… Practice Management Programs: Expansion and Enhancement…Practice Assessment Quiz…non-CME webinar on “Telemedicine and COVID-19: Getting Started”…COVID-19 Resource Center…and partial support of the non-CME webinar on “Managing Your Asthma Patients During COVID-19.”

Commercial Supporters

This activity is supported by independent educational grants from the following commercial supporters: Aimmune Therapeutics Genentech Supporter of the Allied Health Professionals Course. Supporter of the Friday Symposium on “Approach to Diagnosis and Management of Nasal Polyps in the AstraZeneca Biologic Era.” Partial supporter of the Sunday Symposium on “Caring for Patients Across Populations.” Merck Supporter of the Saturday “Not on Thursday Program: CSL Behring Cough.” Partial supporter of the Friday Symposium on “Everything You Wanted to Know About IgG Replacement, But Didn’t Know You Needed to Ask.”

12 29th Annual ACAAI FIT Bowl 5:15 – 6:15 pm Saturday, Nov. 14, 2020

The ACAAI FIT Bowl – now in its 29th consecutive year – is patterned after a popular TV quiz show. This year, 19 teams competed in preliminary rounds and 4 will complete for the coveted FIT Bowl trophy. The teams will test their knowledge, cleverness and ability to listen and quickly respond to questions in this fast-paced event. The questions have been developed by a variety of sources and encompass a wide range of topics including all aspects of allergy/immunology and the history of our profession. The evening is designed to be fun, light-hearted and educational. The first FIT Bowl was conceived by the late Dr. John Selner (ACAAI President 1992-93), and introduced at the College’s 50th Anniversary meeting. Dr. Selner turned to Dr. Kevin Murphy to bring his idea to life and Drs. Bryan Martin and Kevin Murphy have co-chaired the FIT Bowl ever since. The emcee for this year’s program will be Dr. Bryan Martin.

FINAL ROUND

TEAM 1 TEAM 2

Drs. Jun Mendoza and Samuel Weiss Drs. Luke Pittman and Aubri Waters Wilford Hall Ambulatory Surgical Center NCC at Walter Reed National Military Med. Ctr.

TEAM 3 TEAM 4

Drs. Venkatesh Sabhae-Gangadharappa and Drs. Monica Kraft and Dylan Timberlake Alexander Babazadeh Ohio State University SUNY Downstate Medical Center

Continues next page

Supported by DBV Technologies

LIVE RECORDED RECORDED+ 13 FIT Bowl Winning Teams

YEAR FIRST PLACE TEAM MEMBERS

2019 Wilford Hall Ambulatory Surgical Center Drs. Brittanie Neaves and Geoffrey Carlson 2018 University of Tennesse and Wilford Hall Drs. Anita Sivam and Brittanie I. Neaves 2017 Mayo Clinic Drs. Joshua M. Dorn and Caitlin McNulty 2016 Children’s Mercy Hospitals & Clinics Drs. Brooke Polk and Hani Hadi 2015 Wilford Hall Medical Center Drs. Derek Smith and Katherine Tille 2014 Wilford Hall Medical Center Drs. Derek Smith and Priscilla Wong 2013 University of Texas Southwestern Medical Center Drs. Merin Kuruvilla and Sharon Deol 2012 Wilford Hall Medical Center Drs. Scott Dickson and David Rose 2011 Wilford Hall Medical Center Drs. Shayne Stokes and Jeremy Sikora 2010 Wilford Hall Medical Center Drs. Monica Johnson and Mark Stahl 2009 Duke University Medical Center Drs. Pooja Varshney and Rafael Firszt 2008 Medical College of Wisconsin Drs. Anita Gheller-Rigoni and Amit Kumar 2007 Medical College of Wisconsin Drs. Titus Chang and Monica Vasudev 2006 Wilford Hall Medical Center Drs. Christopher Calabria and Stephen E. Scranton 2005 Medical College of Georgia Drs. Cristina M. Mazzoni and Jason R. Perry 2004 Wilford Hall Medical Center Drs. Rajiv Arora and Eric Meier 2003 Cleveland Clinic Drs. Todd Rambasek and Hary Katz 2002 Wilford Hall Medical Center Drs. Daniel R. More and Ronald W. England 2001 Medical College of Georgia Drs. William A. McCann and Reid F. Johnstone 2000 Wilford Hall Medical Center Drs. William T. Boleman and Diane C. Napoli 1999 Medical College of Georgia Drs. Marc Cromie and Andrea Lantz 1998 Medical College of Georgia Drs. Marc Cromie and Jack L. Armstrong 1997 Wilford Hall Medical Center Drs. Joshua S. Jacobs and Russel Walker 1996 Wilford Hall Medical Center Drs. Joshua S. Jacobs and Larry L. Hagan 1995 Wilford Hall Medical Center Drs. Larry Hagan and Christine Schafer 1993 Wilford Hall Medical Center – Air Force Fellowship Drs. William Butler and James Quinn 1992 The Long Island Jewish Hospital Drs. Steven Smith and David Wertheim

Drs. Brittanie Neaves and Geoffrey Carlson of Wilford Hall proudly show the 1st place trophy won at the 28th Annual FIT Bowl last year.

LIVE RECORDED RECORDED+ 14 Special Announcements

Annual Meeting Website College Booth Maximize your time at the meeting! Find schedules, Visit the College booth in the virtual exhibit hall to download handouts and access all the information you learn about valuable member resources available need at annualmeeting.acaai.org. online on the College website, in the College Learning Connection and the Practice Management Center. Sign Dates and Times on to a letter to policymakers in support of our advocacy for allergists and patients. The virtual meeting program will be held on the following dates. All sessions are listed in Central Standard Time (CST). Credit Claiming For your convenience, the College uses an online Friday, November 13 . . . . 7:30 am – 6:30 pm CST evaluation and credit claiming system. This system Saturday, November 14 . . . 7:00 am – 7:15 pm CST allows you to complete evaluations and claim credit for Sunday, November 15 . . . .7:00 am – 4:30 pm CST sessions attended. After completing an annual meeting evaluation, you will be able to save and/or print your E-posters certificate. Complete details can be found on page 22. E-posters go live at 9:30 am CST on Friday, November 13 and are accessible on demand 24/7. Disclaimer Search for specific topics or browse at your leisure. The primary purpose of the ACAAI Annual Scientific New for 2020: E-posters will be accompanied by an Meeting is educational. Information, as well as audio/visual presentation delivered by the presenting technologies, products and/or services discussed, is author. intended to inform participants about the knowledge, E-posters will remain viewable on demand for techniques and experiences of specialists who are 6 months following the Annual Meeting at willing to share such information with colleagues. A college.acaai.org/eposters. diversity of professional opinions exists in the specialty and the views of the College disclaim any and all liability Supported by Sanofi Genzyme and Regeneron for damages to any individual attending this conference and for all claims which may result from the use of Capturing of NPI Numbers information, technologies, products and/or services As part of the health care reform legislation signed into discussed at the conference. law in March 2010, the Physician Payment Sunshine Act requires medical device, biologic and drug companies Foundation to publicly disclose gifts and payments made to The College’s physicians. Foundation, now To help our ACAAI Annual Scientific Meeting exhibitors named the and industry partners in fulfilling the mandatory Allergists’ reporting provisions of the Sunshine Act, the College is Foundation, requesting U.S. health care provider attendees supply has taken a new their 10-digit NPI (National Provider Identifier) number direction in its when registering for the Annual Scientific Meeting. programming to focus more keenly on the needs of The NPI number will be made available to exhibitors in practicing community allergists. Stop by the Foundation their final lead retrieval report they receive at the end booth in the virtual exhibit hall to learn more and get of the meeting so that they can record and track any information on how you can apply for a grant and/or reportable transactions. support these efforts.

15 Special Announcements

Handouts MOC Designated Sessions Session handouts are available for download in the Due to the virtual format of this year’s Annual Meeting, virtual meeting Resource Center or at annualmeeting. ACAAI will not be designating any 2020 Annual Meeting acaai.org/handouts. Handouts for live sessions will also sessions for MOC Part II Self-Assessment Credit. be available for download when you enter the session. However, you’ll find other opportunities to earn MOC Part II self-assessment credit on the College Learning Industry Programs Connection (education.acaai.org). These non-CME commercial presentations and promotional sessions are organized by industry and Networking Goes Viral: #ACAAI20 designed to enhance your meeting experience. All Check out the networking lounge and be a part of attendees are invited to attend these sessions, which are the Annual Meeting conversation! Use #ACAAI20 in scheduled at the start and end of each day and during your meeting-related tweets and follow the College break times between educational sessions. @ACAAI. Also, share Facebook posts from Industry programs will remain viewable on demand facebook.com/TheACAAI. through February 6, 2021 following the Annual Meeting. Oral Abstracts Leaderboard Competition The ACAAI Abstract Review Committee has selected Throughout the meeting, attendees can collect points to only the most dynamic and relevant research qualify for valuable prizes. After logging in to the virtual submissions to share with our Attendees during the meeting platform, click on the trophy icon on the upper 2020 Annual Meeting. More than 35 abstract authors will right corner of your screen to display the leaderboard. deliver cutting-edge research presentations and answer You’ll automatically earn tokens and points by visiting your questions during online chats. various booths in the exhibit hall and participating in other meeting activities. Check the leaderboard Photography/Video Recordings throughout the weekend to see who’s winning! By registering for this meeting, attendees acknowledge Gift cards will be awarded to top scorers. All players with and agree that ACAAI or its agents may take scores over a certain threshold (other than top score photographs or screen shots during events and may winners) will be entered into a raffle for additional prizes. freely use those images in any media for College All tokens/points must be collected by 5:00 pm CST purposes, including, but not limited to, news and on Sunday, November 15. Complete contest rules will be promotional purposes. posted on the Annual Meeting website. The presentations, slides and materials provided in this program are the property of the College or are used Meeting on Demand with permission of the owner. You may not photograph, The recorded educational sessions from the 2020 videotape, audiotape or otherwise record or reproduce Annual Meeting will be hosted on the College Learning any of the presentations without express written Connection in early December. We provide a variety permission from the College. Please note that a single of online packages designed to meet your particular screen shot may accompany a social media post about a needs, from the entire set of recordings to topical presentation. collections. Go to education.acaai.org/ondemand.

16 Special Announcements

Registration Session Types The virtual meeting is accessible only to registered LIVE attendees. Join these sessions at the posted start times to view the live presentations and participate in the online REGISTRATION DEADLINE: discussion. Can’t attend at the designated time? Live NOVEMBER 9, 2020 sessions will be recorded and posted for viewing within 12 hours. Registration includes: • Access to all live and prerecorded sessions until RECORDED+ February 6, 2021. Tune in to these sessions during their scheduled time to • Access to the Annual Literature Review Course.* join in the online chat with session faculty. • Access to the Allied Health and Practice Management Courses.** RECORDED Watch and join these prerecorded sessions as they • Access to cutting-edge research through abstracts become available throughout the day, or view them and e-posters. anytime afterward at your leisure. • Access to the virtual exhibit hall until February 6, 2021. • Virtual networking and social opportunities during the event. Special Needs *In order to attend the full-day Annual Literature In compliance with the Americans with Disabilities Act, Review Course, you must select it on the Optional ACAAI requests that participants in need of special Workshops page when you register. ($75 additional accommodation submit a written request to ACAAI well fee for nonmembers, international affiliate members in advance. and Alliance members.) **In order to be eligible for educational credit for the Tracks Allied Health Professionals Course and the Advanced To make it easier for participants to identify Annual Practice Health Care Providers Course, you must Meeting sessions that are relevant to their practice, the select these on the Optional Workshops page when College has identified nine critical areas for allergy and you register. immunology. These nine areas make up the Annual Meeting Track System.

Virtual Exhibit Hall The virtual exhibit hall opens at 9:30 am CST on Friday, November 13. The College appreciates the support of its exhibitors and urges all attendees to visit over 40 virtual booths in the exhibit hall. Chat with industry representatives during meeting hours, or drop in anytime to view exhibits. Plus, collect tokens for the Leaderboard Contest to qualify to win great prizes! Also visit the College and Foundation booths to learn about resources and opportunities to engage. Exhibits will remain viewable through February 6, 2021.

17 Special Announcements

SPARK Program

The ACAAI SPARK program was developed to help “spark” an interest in residents who might be considering a career in allergy-immunology. This year’s SPARK program provides an opportunity for residents (Pediatric, Internal Medicine, and Med-Peds) to attend this year’s virtual ACAAI Meeting. Awardees will participate in a special Fellows-in-Training (FIT) symposium and attend a wide variety of sessions covering all aspects of allergy-immunology. With the leadership of the Program Directors Committee chaired by Tracy Fausnight, MD, and FIT Representatives, Miriam Samstein, MD, PhD, and Timothy Chow, MD, each SPARK recipient will have a FIT mentor while attending the meeting and beyond.

Catalina Acosta Orozco, MD • Woodhull Medical Center Eosa Adah, MD • Children’s Mercy O. Ann Adebusuyi, MD • Indiana University School of Medicine-Pediatric Residency Program Ruizhi Dong, MD • Ohio State University Wexner Medical Center Internal Medicine Residency Primary Care Track Harris Richard Droghini, MD • Cincinnati Children’s Hospital Charlene M. Dunaway Altamirano, PhD • Cleveland Clinic Internal Medicine Residency Program Rebecca Duron, MD • University of Texas Southwestern Medical Center Daniel Hamilton, MD • University of Buffalo Pediatric Residency Program Ari Heffes-Doon, MD • NYU Langone Health, NYU Winthrop Hospital Derek MacMath, MD • Baylor Internal Medicine-Pediatrics Martin Maldonado-Puebla, MD • George Washington University Internal Medicine Minh Nguyen, DO • Western Michigan University School of Medicine Priya K. Patel, MD • John Hopkins All Children’s Hospital Shipra Rai, MD • General Pediatrics at Cohen Children’s Medical Center Irene Yuan, MD • University of California, Los Angeles

LIVE RECORDED RECORDED+ 18 Education Information

This activity is supported by independent educational Overall Educational Objectives grants from: At the conclusion of this activity, participants should be • Aimmune Therapeutics able to: • AstraZeneca • Identify major advances in key areas of cutting- • CSL Behring edge research in immunologic mechanisms and allergic responses, including anaphylaxis and • Genentech pathophysiology of the upper airways, lungs, eyes, • Merck skin and gastrointestinal tract. • Demonstrate knowledge of basic processes linking molecular and cellular biology and genetics with Target Audience allergic pathophysiology and immunodeficiency. Medical professionals who treat patients with allergic • Translate emerging clinical science principles and/or immunological conditions: to clinical practice in patients with allergic and • Practicing allergist/immunologists immunologic diseases. • Evaluate and implement state-of-the-art diagnostic • Allergy/immunology Fellows-in-Training and therapeutic strategies for treating patients with • Physician assistants allergic and immunologic diseases. • Advanced practice nurses • Explain the impact of environmental exposures and external influences on patients with allergic • Allied health professionals disorders. • Primary care physicians • Recognize emerging trends in the prevalence of • Other medical professionals allergic and immunologic disorders and discuss their impact on public health. • Evaluate the impact of new diagnostic and therapeutic strategies on health care costs and outcomes. • Discuss processes, tools and technologies for the efficient allergy and immunology practice.

LIVE RECORDED RECORDED+ 19 Education Information

Disclosure Statement Credit Designation As required by the Accreditation Council for Continuing The American College of Allergy, Asthma & Medical Education (ACCME) and in accordance with the Immunology (ACAAI) designates this live activity for American College of Allergy, Asthma & Immunology a maximum of 31.5 AMA PRA Category 1 Credit(s). (ACAAI) policy, the College must identify and resolve Physicians should claim only the credit commensurate conflicts of interest for all individuals responsible for with the extent of their participation in the activity. the development, management, presentation, and/ The continuing medical education activity has been or evaluation relevant to a CME activity. Disclosed reviewed by the American Academy of Pediatrics (AAP) information is reviewed in advance in order to manage and is acceptable for a maximum of 31.5 AAP credits. and resolve any potential conflicts of interest. Disclosure These credits can be applied toward the AAP CME/CPD in no way implies that the information presented is Award available to Fellows and Candidate Members of biased or of lesser quality; it is incumbent upon course t he A A P. participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Advanced Practice Health Care Providers Course: This activity has been designated for up to Specific disclosure information for the 2020 Annual 4.75 Continuing Education contact hours. Meeting is conveniently located on the Annual Meeting website at college.acaai.org/disclosures. Allied Health Professionals Course: This activity has been designated for up to 6.75 Continuing Education contact hours. Accreditation Statements The virtual meeting is considered a live activity The American College of Allergy, scheduled for the dates of November 13 – 15. In order to Asthma & Immunology (ACAAI) is earn credit, you must log into the meeting during those accredited by the Accreditation dates. Credit claimed should be commensurate with Council for Continuing Medical your participation during that period. Education (ACCME) to provide continuing medical education for physicians. The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 31.5 contact hours.

LIVE RECORDED RECORDED+ 20 Maintenance of Certification

Due to the virtual format of this year’s Annual Meeting, Disclaimer ACAAI will not be designating any 2020 Annual Meeting The primary purpose of the ACAAI Annual Scientific sessions for MOC Part II Self-Assessment Credit. Meeting is educational. Information, as well as However, you’ll find other opportunities to earn MOC technologies, products and/or services discussed, Part II self-assessment credit at the College Learning is intended to inform participants about the Connection (education.acaai.org). knowledge, techniques and experiences The American Board of Allergy and Immunology’s of specialists who are willing to share such (ABAI) Maintenance of Certification (MOC) program information with colleagues. A diversity of facilitates a physician’s commitment to lifelong learning. professional opinions exists in the specialty Part II of ABAI’s MOC program requires that diplomates and the views of the College disclaim any obtain 25 CME credits in the areas of allergy and/or and all liability for damages to any individual immunology on an annual basis. The CME credits for the attending this conference and for all claims Annual Meeting can be used to satisfy this requirement. which may result from the use of information, In addition to the required 25 CME credits, the ABAI technologies, products and/or services recommends that six of the CME credits also qualify as discussed at the conference. Self-Assessment credit (aka MOC Part II credit). ACAAI seamlessly transfers your Annual Meeting CME and MOC Part II credits to the ABAI at the end of the calendar year. Please note that faculty cannot earn CME or MOC Part II credit for their presentations.

Core Competencies ACAAI is committed to providing educational activities that align with the ABAI Core Competencies, which include: • Patient Care and Procedural Skills • Medical Knowledge • Practice-based Learning and Improvement • Interpersonal and Communication Skills • Professionalism • Systems-based Practice

LIVE RECORDED RECORDED+ 21 Evaluation and Credit Claiming

This year’s virtual meeting is considered a “live” event for Certificates: credit purposes. That means credit can only be claimed • CME Certificates will be awarded to physicians only, if you are logged into the meeting during November per the American Medical Association (AMA PRA 13-15. Credit is calculated at daily maximum of 10.5 Handbook, p. 8). credits, for a 3-day maximum of 31.5 credits. For your convenience, the College uses an online evaluation and • Certificates of Attendance will be awarded to any non- credit claiming system for the 2020 Annual Scientific physician participants who complete the evaluation Meeting. This system allows you to complete evaluations and credit claiming. and claim credit for sessions attended. After completing • CBRN credit certificates will be awarded to nurses and an overall meeting evaluation, you will be able to save nurse practitioners. and/or print your certificate. You may complete your Visit annualmeeting.acaai.org for additional information. evaluations and claim credit anytime between the meeting and the end of this year; however, we strongly urge you do this sooner rather than later! Replacement Certificates: Once you have claimed credit for the 2020 Annual How to log into the evaluation and Meeting, your certificate will always be available on the credit claiming system: College Learning Connection (education.acaai.org). Log in using your College username/password, and click 1) Go to annualmeeting.acaai.org. “My Account,” then “My Learning” to find your learning 2) Click the “Claim Credit” button. transcript. 3) Log in using your last name and ACAAI ID number. 4) Complete the evaluations and claim your credit for the sessions you attended. 5) Complete the overall meeting evaluation. 6) Save and/or print your certificate.

Please complete the evaluation and credit claiming by December 31, 2020.

LIVE RECORDED RECORDED+ 22 Schedule at a Glance All sessions are listed in Central Standard Time (CST).

Friday, November 13

7:30 – 8:00 am CST 1:00 – 2:30 pm CST

Opening Ceremony and Welcome Announcements COVID-19 and Its Impact on Our World, Our Patients and Ourselves

8:00 – 9:30 am CST Hot Topics in Immunotherapy

Presidential Plenary: The Changing Payment Don’t Be Rash! Assessing Contact Dermatitis System – Challenge Accepted! The Spectrum of Dysfunctional Airways Practice Management in a Changing Landscape – 9:30 am CST Efficiency and Legal Issues

Virtual Exhibit Hall Opens E-posters Open 2:35 – 3:00 pm CST

Non-CME Industry Programs: Not for Credit 9:35 – 10:00 am CST Understanding Nasal Polyposis Non-CME Industry Program: Not for Credit Type 2 Inflammation Type 2 Inflammation in Asthma

3:00 – 4:30 pm CST 10:00 – 11:30 am CST Addressing Racial and Ethnic Disparities in Allergy/ Guiding Patients Through Peanut Immunotherapy Immunology Populations Options Vaccines: The Good, the Bad and the Scary Approach to Diagnosis and Management of Nasal Polyps in the Biologic Era Chronic Rhinosinusitis: Prevention, Treatment and Surgery Everything You Wanted To Know About IgG Replacement, but Didn’t Know You Needed To Ask Identification and Management of Infant Anaphylaxis Joint ACAAI/AAP-SOA Session – 7 for 11: Allied Health Professionals Program – Inside Out: Hot Topics in Pediatric A/I How To Perform an Environmental Assessment of Practice Management in a Changing Landscape – Our Allergic Patients Billing and Coding Update Practice Management in a Changing Landscape – Telemedicine and Cybersecurity 11:35 am – 12:30 pm CST

Non-CME Industry Programs: Not for Credit 4:30 – 5:15 pm CST

PALFORZIA® [Peanut (Arachis hypogaea) Allergen Town Hall Meeting presented by ACAAI House of Powder-dnfp] From Evidence to Practice: The First Delegates FDA-Approved Treatment for Peanut Allergy Investigating the Role of Eosinophils in Health, Airway Disease, and Hypereosinophilic Disorders Rediscover Prevention: Proven Efficacy for Patients With HAE

LIVE RECORDED RECORDED+ 23 Schedule at a Glance All sessions are listed in Central Standard Time (CST).

Friday, November 13 (Continued)

4:30 – 5:30 pm CST 5:30 – 6:30 pm CST

Distinguished Industry Oral Abstracts – Non-CME Industry Programs: Not for Credit Session A TSLP: A Key Epithelial Cytokine at the Top of the Distinguished Industry Oral Abstracts – Asthma Inflammatory Cascade Session B A Focus on Type 2 Inflammation in Asthma See EoE: A Closer Look at Diagnosing and Managing Eosinophilic Esophagitis

Saturday, November 14

7:00 – 7:55 am CST 9:35 – 10:00 am CST

Non-CME Industry Program: Not for Credit Non-CME Industry Programs: Not for Credit Systemic Mastocytosis: An Allergist/Immunologist Managing Food Allergy During the COVID-19 Perspective on Diagnosis and Treatment Pandemic and Implications for the Future Understanding the Needs of Infants and Toddlers 8:00 – 8:45 am CST With Life-Threatening Allergies

Advanced Practice Program – Asthma/COPD Overlap 10:00 – 11:00 am CST Advanced Practice Program – Clinical Pearls From 8:00 – 9:30 am CST the Dermatologist

It’s Time To Individualize Our Approach to Diagnosis and Testing 10:00 – 11:30 am CST An International Perspective on Cutting-edge Food Nuts and Bolts of Telemedicine Allergy Research School Health for the Allergist The Not on Thursday Program: Cough – Part 1 The Not on Thursday Program: Biologics – Part 1 Who Needs Mast Cells Anyway: Non-IgE-mediated Joint ACAAI/WAO Presentation – World Allergy Food Allergy Forum: Corticosteroid Stewardship in Allergic Emerging Concepts of IL-5 and Eosinophils in Diseases Respiratory Disease Oral Abstracts – Angioedema/Urticaria Oral Abstracts – Adverse Drug Reactions/Clinical Joint ACAAI/AAAAI Session – Ensuring the Success Immunology of Academic Allergy

LIVE RECORDED RECORDED+ 24 Schedule at a Glance All sessions are listed in Central Standard Time (CST).

Saturday, November 14 (Continued)

11:35 am – 12:30 pm CST 3:00 – 4:30 pm CST

Non-CME Industry Programs: Not for Credit FIT Integrated Educational Program and Business Meeting Targeting a Common Contributor to Severe Asthma The Not on Thursday Program: Biologics – Part 2 A Treatment Option for Mild-to-Moderate Atopic Beyond Antihistamines: Strategies for Relieving Dermatitis in Patients Aged 3 Months and Older Antihistamine-refractory Chronic Urticaria The Role of Digitally Connected Inhalers: An “I’m Sorry Smokey, You Are Over the Line!” The Introduction to Digihaler® Technology Case for Better Understanding of Allergenic Thresholds and How This Can Improve Patient Care 1:00 – 2:30 pm CST CAP (Continuous Assessment Program) Review – Game Show – What’s That Rash? Doctor, What’s Session 2 Wrong With My Skin? Oral Abstracts – Allergy Diagnostics/Aerobiology/ The Not on Thursday Program: Cough – Part 2 Food Allergy How to Discuss Complementary and Alternative Editor’s Pick – Best Articles from Annals of Allergy, Medicine With Patients and Implement Into Asthma & Immunology Practice Advanced Practice Program – Psychosocial Oral Abstracts – Asthma/Rhinitis Management of Food Allergy and Atopic CAP (Continuous Assessment Program) Review – Dermatitis Session 1 Advanced Practice Program – Food for Thought on 4:30 – 5:15 pm CST Anaphylaxis ACAAI 2020 Annual Business Meeting

2:35 – 3:00 pm CST 5:15 – 6:15 pm CST Non-CME Industry Program: Not for Credit 29th Annual FIT Bowl Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease 6:15 – 7:15 pm CST

Non-CME Industry Programs: Not for Credit Disrupting Decades of Unmet Need: Targeting Uncontrolled Asthma & SABA Reliance With PRECISION The Journey Towards Controlled Asthma: Shifting the Treatment Paradigm Keeping the Cat: A Transformational Approach to Reducing Fel d 1 Through the Cat’s Diet

LIVE RECORDED RECORDED+ 25 Schedule at a Glance All sessions are listed in Central Standard Time (CST).

Sunday, November 15

8:00 – 8:45 am CST 11:35 am – 12:30 pm CST

Allied Health Professionals Program – The Role of Non-CME Industry Programs: Not for Credit the Nurse in the Care and Management of Patients Eosinophilic Immune Dysfunction With Atopic Dermatitis Clinical and Real-World Evidence for Using a Biologic to Treat Severe Eosinophilic Asthma 8:00 – 9:00 am CST Deepening Our Understanding: Cytokine Signaling Oral Abstracts – Clemens von Pirquet Awardees and the JAK/STAT Pathway in Atopic Dermatitis Building ABAI Continuing Certification Together 1:00 – 2:30 pm CST

8:00 – 9:30 am CST Masqueraders of Common Allergic Conditions How To Implement Updates From the Latest The AAAAI/ACAAI/CSACI North American Food Clinical Guidelines Into Practice Allergy Prevention Guidelines SLIT Versus SCIT – Let the Battle Begin Literature Review – Afternoon Program Part 1 Literature Review – Morning Program Part 1 The Influence of Social Media on Patients and Medical Decision Making Itching to Help: Diagnosis and Management of Itch and Dermatitis in Special Populations Oral Abstracts – Food Allergy Allied Health Professionals Program – Oral 10:00 – 11:30 am CST Challenge Update

Coding and Government Relations 3:00 – 4:30 pm CST Caring for Patients Across Multiple Populations GINA Versus NHLBI Asthma Guidelines: How Do Literature Review – Morning Program Part 2 We Reconcile Differences? Marijuana, E-cigs, Vaping, Hookah and More: How The Challenges of Severe Conjunctival To Discuss With Patients Inflammation EAACI – Allergen Immunotherapy in 2020: Still a Literature Review – Afternoon Program Part 2 Valid Intervention? Microbiome Across the Spectrum of Allergic Oral Abstracts – COVID19/Quality Improvement Conditions Allied Health Professionals Program – Let’s Work Hereditary Angioedema: Rising to the Challenge Together: Collaborative Patient Care Models in Community Allergy Practices Allied Health Professionals Program – Food Allergy Mimickers: Non-IgE Food Intolerances

LIVE RECORDED RECORDED+ 26 Named Lectures

Each year, the American College of Allergy, Asthma & Immunology presents special named lectures during the Annual Scientific Meeting. The allergists selected to present named lectures embody the high standards and achievements of the physicians for whom the lectures are named. The College is proud to present the following named lectures at its 2020 Annual Scientific Meeting.

Edward J. O’Connell Bela Schick Lecture Memorial Lecture Then, Now and Where Do We Go From Here? Lessons Learned From the Skin: How Allergists Can Saturday, Nov. 14, 9:05 – 9:30 am CST Help Our Patients With Their Common Concerns James M. Tracy, DO, FACAAI Saturday, Nov. 14, 8:45 – 9:05 am CST The annual Bela Schick Lecture is named in honor of one Luz S. Fonacier, MD, FACAAI of medicine’s most respected scientists. Dr. Bela Schick This annual lectureship was established to honor the was born in Hungary and attended medical school legacy of Dr. Edward J. O’Connell, a past president of in Austria. After serving as Extraordinary Professor the College and former Annals editor-in-chief, who was a of Children’s Diseases at the University of Vienna, he caring, compassionate physician with a life-long passion immigrated to the United States in 1923. He was a for serving children. He was an adept educator and pediatrician at Mt. Sinai in New York for many years, authored nearly 100 original articles, along with many loved by his patients and respected by his fellows. Dr. book chapters related to allergy and immunology. Schick is best known for his work with Clemens von Pirquet on anaphylaxis and for the test he developed to assess immunity in diphtheria.

Watch and listen live! 8:00 – 9:30 am, CST Saturday, Nov. 14

LIVE RECORDED RECORDED+ 27 Friday, November 13

7:30 – 8:00 am CST 9:35 – 10:00 am CST Opening Ceremony and Industry Program Welcome Announcements (See page 64 for details.) J. Allen Meadows, MD, FACAAI, President David R. Stukus, MD, FACAAI, 10:00 – 11:30 am CST Annual Meeting Program Chair Guiding Patients Through Peanut Immunotherapy Options Moderators: David R. Stukus, MD, FACAAI, and David M. Fleischer, MD, FACAAI We now have multiple options available for patients Dr. Meadows Dr. Stukus with peanut allergy. This session will discuss how to use shared decision-making to help patients understand treatment options and help allergists understand what 8:00 – 9:30 am CST their patients value. Presidential Plenary Track: Food & Drug Allergy and GI Disorders

The Changing Payment System – 10:00 am Welcome and Introductions Challenge Accepted! David R. Stukus, MD, FACAAI, and David M. Fleischer, MD, FACAAI Moderator: J. Allen Meadows, MD, FACAAI 10:03 am Non-FDA-Approved Oral Immunotherapy You can play a significant role in ensuring that payment Arnon Elizur, MD models for hospitals and private practice are fair and comprehensive. Get insight into the future of reimbursement 10:20 am FDA-Approved Oral Immunotherapy following the presidential election and months spent Edwin H. Kim, MD, FACAAI adjusting for the current and future impact of COVID-19. 10:35 am Epicutaneous Immunotherapy Track: Practice Management / Professional Issues Julie Wang, MD, FACAAI

8:00 am Welcome and Introductions 10:50 am Ongoing Avoidance Without Treatment J. Allen Meadows, MD, FACAAI Jay A. Lieberman, MD, FACAAI 8:03 am If You’re Not at the Table, You’re Probably 11:05 am Using Shared Decision-making to Guide on the Menu! Patients Through the Options Bill Finerfrock, President, Capitol Associates; Matthew C. Greenhawt, MD, MSc, MBA, Consultant, Advocacy Council of ACAAI FACAAI 11:20 am Questions and Discussion 8:30 am Keynote Presentation 11:30 am Adjourn Why “Value-based Payment” Isn’t Working – And How Physicians Can Fix It Harold D. Miller, President and CEO Center for Healthcare Looking for the Quality and Payment Reform Annual Literature Review? 9:20 am Questions and Discussion It’s on Sunday this year! 9:30 am Adjourn

LIVE RECORDED RECORDED+ 28 Friday, November 13

10:00 – 11:30 am CST 10:00 – 11:30 am CST Approach to Diagnosis and Everything You Wanted To Know Management of Nasal Polyps in About IgG Replacement, but Didn’t the Biologic Era Know You Needed To Ask Moderators: John B. Hagan, MD, FACAAI, and Moderators: Purvi S. Parikh, MD, FACAAI, and Puneet Shroff, MD, FACAAI Lisa J. Kobrynski, MD, MPH, FACAAI Supported by an independent educational grant from Supported in part by an independent educational grant Genentech from CSL Behring This session will review nasal polyps and discuss Immunoglobulin replacement can be effective at the medical and surgical management of specific preventing infection and treating certain inflammatory endotypes, with a focus on biologic therapies. disorders. However, treatment is often complicated by adverse reactions. Multiple gamma globulin products Track: Clinical Immunology and Autoimmune and Biologicals are currently available, and choosing the best product for the individual patient can decrease the burden of 10:00 am Welcome and Introductions treatment and improve adherence to this therapy. John B. Hagan, MD, FACAAI, and Track: Clinical Immunology and Autoimmune Puneet Shroff, MD, FACAAI and Biologicals 10:03 am Description of Underlying Endotypes and 10:00 am Welcome and Introductions Visible Phenotypes Associated With Nasal Purvi S. Parikh, MD, FACAAI, and Polyps Lisa J. Kobrynski, MD, MPH, FACAAI Sandra Y. Lin, MD 10:03 am Immunoglobulin Replacement: The Proper 10:30 am Current Approach to Medical and Surgical Indications for Starting Therapy and Management of Nasal Polyps Continuing Therapy Joshua Levy, MD Vivian P. Hernandez-Trujillo, MD, FACAAI 10:55 am The Use of Biologics in Nasal Polyps Based 10:40 am Immunoglobulin Replacement: Pearls for on Disease Mechanism of Individual Managing Antibody Deficient Patients on Phenotypes Immunoglobulin Replacement Therapy Merin E. Kuruvilla, MD Mark M. Ballow, MD, FACAAI 11:20 am Questions and Discussion 11:20 am Questions and Discussion (Online Chat) 11:30 am Adjourn 11:30 am Adjourn

Time Zones All sessions are listed in Central Standard Time (CST). Don’t forget to convert them to your local time zone when planning your schedule!

LIVE RECORDED RECORDED+ 29 Friday, November 13

10:00 – 11:30 am CST 10:00 – 11:30 am CST Joint ACAAI/AAP-SOA Session Practice Management in a 7 for 11: Hot Topics in Pediatric A/I Changing Landscape – Moderator: Todd A. Mahr, MD, FACAAI Billing and Coding Update Each of the 7 presenters will have only 11 minutes to Moderator: Thomas J. Derrico deliver insightful, targeted and dynamic information on Track: Practice Management / Professional Issues their assigned topics. Track: Dermatology 10:00 am Welcome and Introductions Thomas J. Derrico Welcome and Introductions 10:10 am Coding/Billing/Regulatory Update Todd A. Mahr, MD, FACAAI Gary N. Gross, MD, FACAAI Asthma 11:00 am ACAAI College Resources To Help Angela D. Hogan, MD, FACAAI Your Practice Food Allergy – Non-treatment Jennifer Pfeifer, MBA, CMPE J. Wesley Sublett, MD, MPH, FACAAI 11:10 am Questions and Discussion (Online Chat) Food Allergy – Treatment 11:30 am Adjourn J. Andrew Bird, MD, FACAAI Biologics Carla M. Davis, MD, FACAAI 11:30 am Adjourn11:35 am – 12:30 pm CST Anaphylaxis Industry Programs Julie Wang, MD, FACAAI (See page 64 for details.) Immunology Mary Beth Fasano, MD, MSPH, FACAAI Epidemiology Ruchi Gupta, MD, MPH Adjourn

LIVE RECORDED RECORDED+ 30 Friday, November 13

1:00 – 2:30 pm CST 1:00 – 2:30 pm CST COVID-19 and Its Impact on Our Hot Topics in Immunotherapy World, Our Patients and Ourselves Moderators: Ellen R. Sher MD, FACAAI, and Moderator: Brian T. Kelly, MD, MA, FACAAI Peter J. Mustillo, MD, FACAAI The crushing coronavirus emergency has attacked While we currently have 19 standardized subcutaneous our physicians on all fronts: caring for compromised allergens in the United States, there are several different patients, dispelling harmful misinformation, significantly methods used to describe standardized allergens. changing business models, keeping our families safe In Europe there are standardization terms that are and maintaining the agility to forge ahead. This session unfamiliar to many U.S. allergists. It is important for the will provide strategies to help our patients and ourselves practicing allergist to understand the methodologies successfully survive this pandemic for the standardization of allergen extracts and how the standardized allergens may influence clinical allergen 1:00 pm Welcome and Introductions immunotherapy in the U.S. Brian T. Kelly, MD, MA, FACAAI Track: Immunotherapy and Diagnostics 1:03 pm How Best to Battle the Infodemic 1:00 pm Welcome and Introductions Timothy Caulfield, LLM, FRSC, FCAHS Ellen R. Sher MD, FACAAI, and 1:25 pm Immunology, Risk Factors, and Treatment of Peter J. Mustillo, MD, FACAAI COVID-19 1:03 pm Are You Dosing Properly? Brian Lipworth, MD, FACAAI Harold S. Nelson, MD, FACAAI 1:50 pm Learning To Live With COVID-19: Strategies 1:30 pm Do Patients Receiving Subcutaneous To Help Medical Professionals and Our Immunotherapy Need To Have an Patients Epinephrine Auto-injector Prescribed? Jessi Gold, MD, MS David I. Bernstein, MD, FACAAI 2:15 pm Questions and Discussion 1:55 pm Ultra-rush, Rush and Standard Build-up 2:30 pm Adjourn Dosing: Who? When? Why? Where? And How? Jay M. Portnoy, MD, FACAAI 2:20 pm Questions and Discussion 2:30 pm Adjourn

Scheduled Break Times Grab your favorite snack and visit the interactive virtual exhibit hall, e-posters and the networking lounge.

LIVE RECORDED RECORDED+ 31 Friday, November 13

1:00 – 2:30 pm CST 1:00 – 2:30 pm CST Don’t Be Rash! The Spectrum of Assessing Contact Dermatitis Dysfunctional Airways Moderators: Sandra M. Gawchik, DO, FACAAI, and Moderators: Jeremy S. Katcher, MD, FACAAI, and Tammy Peng, MD Michael R. Rupp, MD, FACAAI From basic science to the clinical conundrums, this This session will review dysfunctional breathing in session will cover how to evaluate and manage patients children and adults. Various aspects of the upper airway with contact dermatitis. will be discussed, including how allergists can help identify and treat patients who have obstructive sleep Track: Dermatology apnea and exercise-induced laryngeal obstruction. 1:00 pm Welcome and Introductions Track: Asthma and Respiratory / Sleep Disorders Sandra M. Gawchik, DO, FACAAI, and Welcome and Introductions Tammy Peng, MD Jeremy S. Katcher, MD, FACAAI, and 1:03 pm Interpretation of Skin Biopsy Results Michael R. Rupp, MD, FACAAI in Eczema Obstructive Sleep Apnea: More Than Snoring – Whitney A. High, MD, MEng Allergists Can Help 1:28 pm Clinical Pearls and Pitfalls in Evaluating Timothy J. Craig, DO, FACAAI Patients With Contact Dermatitis Diagnosing Exercise-induced Laryngeal Obstruction Sharon E. Jacob, MD and Dysfunctional Breathing 1:53 pm How To Help Patients With Contact James Tod Olin, MD, MSCS Dermatitis Before and After Patch Testing Advances in Treatment and Behavioral Interventions Jeff J. Yu, MD To Treat EILO 2:20 pm Questions and Discussion (Online Chat) Monica Shaffer, MA, CCC-SLP 2:30 pm Adjourn Adjourn

1:00 – 2:30 pm CST Practice Management in a Changing Landscape – Efficiency and Legal Issues Moderator: Thomas J. Derrico Track: Practice Management / Professional Issues

1:00 pm Welcome and Introductions Thomas J. Derrico 1:03 pm Practice Efficiency: Work Flow/Lean Six Sigma Michael Tankersley, MD, MBA, FACAAI 1:35 pm Legal Issues in Practice Denise Yarborough, JD, Esq. 2:20 pm Questions and Discussion (Online Chat) 2:30 pm Adjourn

LIVE RECORDED RECORDED+ 32 Friday, November 13

2:35 – 3:00 pm CST 3:00 – 4:30 pm CST Industry Programs Vaccines: The Good, the Bad (See page 65 for details.) and the Scary Moderators: Melinda M. Rathkopf, MD, FACAAI, and Mervat Nassef, MD, FACAAI 3:00 – 4:30 pm CST Recent events, including an unprecedented global Addressing Racial and pandemic and the 2019 measles outbreak, highlight the importance of universal vaccination. However, Ethnic Disparities in parents of young children do not always comply Allergy/Immunology Populations with recommended vaccinations for various reasons, including fear of vaccine-related adverse reaction. Moderator: David R. Stukus, MD, FACAAI Allergists/immunologists can play an important role in This session will discuss how allergists can understand improving vaccination rates by dispelling unfounded racial and ethnic disparities and address these issues fears, evaluating patients with suspected adverse with respect to caring for patients with food allergy, reactions and assessing risk in patients with severe asthma and atopic dermatitis. allergy to vaccine ingredients. Track: Population Health and Infectious Diseases / Track: Population Health and Infectious Diseases / International Travel International Travel

3:00 pm Welcome and Introductions 3:00 pm Welcome and Introductions David R. Stukus, MD, FACAAI Melinda M. Rathkopf, MD, FACAAI, and Mervat Nassef, MD, FACAAI 3:03 pm Atopic Dermatitis Disparities Jonathan Silverberg, MD, PhD, MPH 3:03 pm Lessons Learned From Recent Outbreaks and How To Deal With Vaccine Hesitancy 3:30 pm Asthma Disparities Lisa Saiman, MD, MPH Tamara T. Perry, MD 3:30 pm Evaluation and Management of Adverse 3:55 pm Food Allergy Disparities Reactions to Vaccines Carla Davis, MD, FACAAI John M. Kelso, MD, FACAAI 4:20 pm Questions and Discussion 3:55 pm Vaccine Development: Why? When? How? 4:30 pm Adjourn Julie E. Ledgerwood, DO 4:20 pm Questions and Discussion 4:30 pm Adjourn

LIVE RECORDED RECORDED+ 33 Friday, November 13

3:00 – 4:30 pm CST 3:00 – 4:30 pm CST Chronic Rhinosinusitis: Prevention, Identification and Management Treatment and Surgery of Infant Anaphylaxis Moderator: J. Wesley Sublett, MD, MPH, FACAAI Moderators: Michael Pistiner, MD, MMSc, FACAAI, and Kristin C. Sokol, MD, MS, MPH, FACAAI Chronic rhinosinusitis is a common condition impacting millions of patients. This session will discuss the Infants present with different signs and symptoms of common causes and contributing factors that allergists anaphylaxis, as compared to older patients. Attendees should consider during evaluation. In addition, various will be able to identify anaphylaxis in infants and medical and surgical treatment approaches will be educate the parents/ family members of these infants. discussed, including how to discuss and choose the best Proper management and treatment will also be options for each individual patient. reviewed. Track: Rhinitis / Sinusitis / Ocular and Anaphylaxis Track: Rhinitis / Sinusitis / Ocular and Anaphylaxis

Welcome and Introductions 3:00 pm Welcome and Introductions J. Wesley Sublett, MD, MPH, FACAAI Michael Pistiner, MD, MMSc, FACAAI, and Kristin C. Sokol, MD, MS, MPH, FACAAI Causes, Contributing Factors and Evaluation of the Patient 3:03 pm Epidemiology and Presentation of Infant Jonathan A. Bernstein, MD, FACAAI Anaphylaxis – Signs and Symptoms Vivian P. Hernandez-Trujillo, MD, FACAAI Medical Therapies Whitney Stevens, MD, PhD 3:30 pm Treatment and Management of Infant Anaphylaxis Today’s Surgical Options and Outcomes Jay A. Lieberman, MD, FACAAI Thomas S. Higgins, MD, MSPH 3:55 pm Infants in the Office Setting: Practical Adjourn Aspects of Early Peanut Introduction and Oral Food Challenges Justin Greiwe, MD, FACAAI 4:20 pm Questions and Discussion (Online Chat) 4:30 pm Adjourn

Thinking about becoming a member? Learn about the benefits here.

LIVE RECORDED RECORDED+ 34 Friday, November 13

3:00 – 4:30 pm CST 4:30 – 5:15 pm CST Practice Management in Town Hall Meeting presented by a Changing Landscape – ACAAI House of Delegates Telemedicine and Cybersecurity All attendees are invited to participate. Learn about Moderator: Thomas J. Derrico new resolutions and what telehealth will look like post COVID-19. Track: Practice Management / Professional Issues Speakers: Welcome and Introductions Curtis L. Hedberg, MD, FACAAI, Speaker of the Thomas J. Derrico ACAAI House of Delegates Bill Finerfrock, President of Capitol Associates, Telehealth in Private Practice: Optimizing and Consultant to Advocacy Council of ACAAI Enhancing for the Future Tania Elliott, MD, FACAAI I. Welcome and Officer Introductions Cyber Security: Recognizing, Assessing and II. Business Meeting Mitigating Risks a. Approve Minutes Joseph Alessi b. Recording Secretary and Super-delegate Voting Resolutions Adjourn c. III. Introduction of State Delegates 3:00 – 4:30 pm CST IV. Summary of Regional Town Hall Meetings Allied Health Professionals Program V. What Will Telehealth Look Like Post COVID-19? Inside Out: How To Perform an Environmental Assessment of Our Allergic Patients Supported by an independent educational grant from Aimmune Therapeutics This session will discuss everything you wanted to know about pollen and molds. It will begin by reviewing pollen identification with seasonal and regional variations. Next, we’ll go indoors and review how to perform a home assessment for allergens in the home. This session is designed for all healthcare workers in the field of allergy. Educational credit for the Allied Health Professionals Course is only available to those who pre-registered for it.

Welcome and Introductions Jodi A. Shroba, MSN, APRN, CPNP Let’s Take It Outside: A Review of Pollens and Molds Amanda L. Michaud, PA-C Bringing It Home: How To Perform a Home Assessment Kevin Kennedy, MPH, CIEC Adjourn

LIVE RECORDED RECORDED+ 35 Friday, November 13

4:30 – 5:30 pm CST 4:30 – 5:30 pm CST Distinguished Industry Distinguished Industry Oral Abstracts – Session A Oral Abstracts – Session B Moderator: Todd A. Mahr, MD, FACAAI Moderator: Melanie A. Ruffner, MD, PhD The College is honored to provide an opportunity for The College is honored to provide an opportunity for industry to update our attendees on the latest research industry to update our attendees on the latest research and developing opportunities for patient treatment. and developing opportunities for patient treatment.

4:30 pm Welcome and Introductions 4:30 pm Welcome and Introductions Todd A, Mahr, MD, FACAAI Melanie A. Ruffner, MD, PhD 4:33 pm Abrocitinib Versus Dupilumab: Time to 4:33 pm Development of an EHR-Based Algorithm Improvement by Body Region (JADE To Identify Patients With Chronic Cough COMPARE) Vishal Bali, MD Marjolein De Brun-Weller, MD 4:43 pm Patients With Chronic Rhinosinusitis 4:43 pm Ligelizumab Achieves Fast Control of With and Without Asthma: A Real-world Symptoms in More Patients With Chronic Experience Spontaneous Urticaria Versus Omalizumab Hector Ortega, MD Thomas Severin, MD 4:53 pm Continued Safety/Efficacy of Omalizumab 4:53 pm Efficacy of Ligelizumab in Patients in Chronic Rhinosinusitis With Nasal Polyps: With Chronic Spontaneous Urticaria An Open-label Extension Study Inadequately Controlled With Omalizumab Philippe Gevaert, MD Gordon Sussman, MD 5:03 pm Questions and Discussion 5:03 pm Berotralstat Reduces Attacks in Patients 5:30 pm Adjourn With Hereditary Angioedema (HAE): APeX-2 Trial 48 Week Results H. James Wedner, MD 5:13 pm Questions and Discussion 5:30 – 6:30 pm CST 5:30 pm Adjourn Industry Programs (See page 65 for details.)

LIVE RECORDED RECORDED+ 36 Saturday, November 14

7:00– 7:55 am CST 8:00 – 9:30 am CST Industry Program An International Perspective (See page 66 for details.) on Cutting-edge Food Allergy Research 8:00 – 9:30 am CST Moderators: Ruchi Gupta, MD, MPH, and It’s Time To Individualize Our Benjamin Prince, MD Approach to Diagnosis and Testing In this session, attendees will be given an in-depth perspective on the outcomes and knowledge gained Moderator: Mark L. Corbett, MD, FACAAI from the Australian HealthNuts prospective, population- This plenary will provide dynamic presentations based food allergy prevalence study at 10 years in surrounding important topics that have evolved in recent terms of the development, risk factors for development years. Allergists are in a unique position to provide and natural history of food allergy. In addition, this education to patients and help them understand their session will detail the next frontier in food allergy risk from various scenarios. The field of component prevention from studies ongoing in the Center for diagnostic testing for food, inhalant and venom Food Allergy Research consortium across Australia, allergens has rapidly expanded, and attendees will learn detailing their work into early tree nut introduction how to utilize and interpret various tests. Attendees will also learn how to apply specialty training in allergy and and how vitamin D, maternal diet and vaccines may immunology to address common concerns from patients influence the development of food allergy in the infant. regarding dermatologic conditions. Lastly, the attendee will learn about cutting-edge ongoing research from Israel regarding tree nut oral Immunotherapy and Diagnostics Track: immunotherapy and how desensitization to one tree nut 8:00 am Welcome and Introductions can protect against multiple tree nut allergies. Mark L. Corbett, MD, FACAAI Track: Food & Drug Allergy and GI Disorders 8:03 am How To Discuss Complicated Concepts Surrounding Risk With Patients 8:00 am Welcome and Introductions Elissa M. Abrams, MD Ruchi Gupta, MD, MPH, and Benjamin Prince, MD 8:25 am Component-resolved Diagnostics – Which Ones Are Ready for Prime Time? 8:05 am The HealthNuts Study at Age 10: Giorgio Walter Canonica, MD Lessons Learned and Future Directions Jennifer Koplin, MD, PhD 8:45 am Edward J. O’Connell Lecture 8:30 am Ahead of the Curve: The Next Wave of Lessons Learned From the Strategies for Preventing Food Allergy Skin: How Allergists Can Help Kirsten Perret, MBBS, FRACP, PhD Our Patients With Their 8:55 am One Nut, Two Nuts, Three Nuts, Four? Common Concerns Achieving Parsimony for Tree Nut Oral Luz S. Fonacier, MD, FACAAI Immunotherapy Arnon Elizur, MD 9:05 am Bela Schick Lecture 9:20 am Questions and Discussion Then, Now and Where Do We Go From Here? 9:30 am Adjourn James M. Tracy, DO, FACAAI

9:30 am Adjourn

LIVE RECORDED RECORDED+ 37 Saturday, November 14

8:00 – 9:30 am CST 8:00 – 9:30 am CST The Not on Thursday Program: Who Needs Mast Cells Anyway: Cough – Part 1 Non-IgE-mediated Food Allergy Moderators: Alan B. Goldsobel, MD, FACAAI, and Moderators: Anna H. Nowak-Wegrzyn, MD, FACAAI, and David R. Stukus, MD, FACAAI Irene Mikhail, MD Supported by an independent educational grant from Non-IgE-mediated food intolerances and allergies are Merck common concerns among patients. This session will From diagnosis to treatment, this session will highlight address the current evidence and understanding of the evolution of cough, current treatment guidance how to recognize the features pertaining to common options, and a look into future therapies. conditions, decide what tests to utilize to assist diagnosis and review treatment options. Track: Asthma and Respiratory / Sleep Disorders Track: Food & Drug Allergy and GI Disorders Welcome and Introductions Alan B. Goldsobel, MD, FACAAI, and Welcome and Introductions David R. Stukus, MD, FACAAI Anna H. Nowak-Wegrzyn, MD, FACAAI, and Irene Mikhail, MD Choosing the Proper Test From Your Diagnostic Tool Belt FPIES – Prevalence, Diagnosis and Management Pearls Mandel R. Sher, MD, FACAAI Terri F. Brown-Whitehorn, MD Kids Are Not Little Adults: Unique Aspects to Eosinophilic Esophagitis Antonella Cianferoni, MD Diagnosis and Treatment of Cough in Children William C. Anderson, MD, FACAAI Allergic Proctocolitis and Other Crimes Against The Future Is Bright: Hopeful Options for Asthma Humanity Attributed to Milk Leonard B. Bacharier, MD, FACAAI J. Andrew Bird, MD, FACAAI Adjourn Adjourn

LIVE RECORDED RECORDED+ 38 Saturday, November 14

8:00 – 9:30 am CST 8:00 – 9:30 am CST Emerging Concepts of IL-5 and Oral Abstracts – Adverse Drug Eosinophils in Respiratory Disease Reactions/Clinical Immunology Moderators: Jeremy S. Katcher, MD, FACAAI, and Moderator: Lisa J. Kobrynski, MD, MPH, FACAAI Alan B. Goldsobel, MD, FACAAI 8:00 am Welcome and Introductions Over the last few years, we have continued to learn Lisa J. Kobrynski, MD, MPH, FACAAI more about how IL-5 and eosinophils often mediate severe asthma and other related conditions. However, 8:03 am Lessons From Antibiotic Oral Challenges in our understanding is still incomplete. The ability to 68 Pediatric Patients at a Tertiary Center determine to what extent this pathway is responsible Grant Pickett, MD for asthma pathophysiology can still be challenging. 8:18 am Short-term Cardiac Outcomes: Aspirin Similarly, with multiple biologics available, it can be Desensitization in Acute Coronary difficult for the asthma specialist to determine which Syndrome specific agent is most appropriate and beneficial Amie Nguyen, MD to the patient. Determining the most accurate and clinically meaningful biomarkers would be a major 8:33 am Diagnosis of Specific Antibody Deficiency step in this process. With better understanding of (SAD): Comparison of Different Diagnostic the pathophysiology, and continuing education of Methods asthma specialists, multiple healthcare benefits could Vivien Pat be realized. Patient care and asthma control would 8:48 am Current Practice of Immunophenotyping improve maximally and most expeditiously with the best Pre- and Post-rituximab Administration choice of biologic being made initially. This would help Di Sun, MD, MPH decrease healthcare dollars spent on exacerbations, ED visits, hospitalizations, as well as minimize patient job/ 9:03 am Questions and Discussion (Online Chat) school absenteeism. 9:30 am Adjourn Track: Asthma and Respiratory / Sleep Disorders

8:00 am Welcome and Introductions Jeremy S. Katcher, MD, FACAAI, and Alan B. Goldsobel, MD, FACAAI 8:03 am Subtypes of Severe Asthma With Emphasis on Eosinophilic Subtype William C. Anderson, MD, FACAAI 8:28 am Biomarker Interpretations and How This Would Aid in Treatment Choice and Prognosis Prediction Leonard B. Bacharier, MD, FACAAI 8:53 am IL-5/Eosinophil-related Conditions Other Than Severe Eosinophilic Asthma Princess Ogbogu, MD, FACAAI 9:20 am Questions and Discussion (Online Chat) 9:30 am Adjourn

LIVE RECORDED RECORDED+ 39 Saturday, November 14

8:00 – 8:45 am CST 10:00 – 11:30 am CST Advanced Practice Program – Nuts and Bolts of Telemedicine Asthma/COPD Overlap Moderators: Jay M. Portnoy, MD, FACAAI, and Moderator: Jodi A. Shroba, MSN, APRN, CPNP David M. Lang, MD, FACAAI Previously thought to be two separate disease states, This session will focus on helping practicing allergists it is now widely accepted that some patients exhibit a set up a telemedicine program in their office, as well as mixed asthma and COPD presentation. This session bill and get paid for providing the service. Attendees will explore the diagnosis and management of this will also get tips on how to see patients using this challenging patient population. technology. Educational credit for the Advanced Practice Health Track: Practice Management / Professional Issues Care Providers Course is only available to those who pre- 10:00 am Welcome and Introductions registered for it. Jay M. Portnoy, MD, FACAAI, and David M. Lang, MD, FACAAI Welcome and Introductions Jodi A. Shroba, MSN, APRN, CPNP 10:03 am The Changing Paradigm of Telemedicine Jennifer A. Shih, MD Asthma/COPD Overlap Michelle R. Dickens, MSN, RN, FNP-C, AE-C 10:30 am How To Implement Telemedicine Into Your Adjourn Practice Tania Elliott, MD, FACAAI 10:55 am Coding and Billing for Telemedicine Services: How To Get Started and How To 9:35 – 10:00 am CST Get Paid Sakina S. Bajowala, MD Industry Programs (See page 67 for details.) 11:20 am Questions and Discussion 11:30 am Adjourn

Scheduled Break Times Grab your favorite snack and visit the interactive virtual exhibit hall, e-posters and the networking lounge.

LIVE RECORDED RECORDED+ 40 Saturday, November 14

10:00 – 11:30 am CST 10:00 – 11:30 am CST School Health for the Allergist The Not on Thursday Program: Moderators: Bruce J. Lanser, MD, FACAAI, and Biologics – Part 1 Irene Mikhail, MD Moderators: John J. Oppenheimer, MD, FACAAI, and With the rise in prevalence of multiple childhood Brian T. Kelly, MD, MA, FACAAI allergic diseases, schools have been forced to deal with Cutting-edge biologics can offer promising results. This management facets to ensure that students remain safe session will focus on the latest information on current and healthy at school. As well, schools have represented and emerging applications for sinus disease, skin opportunities to reach populations who may otherwise afflictions and food allergy. lack access to healthcare services to both diagnose and manage allergic diseases. This session will detail Track: Immunotherapy and Diagnostics the approach to the care of managing the patient with allergic disease in the school setting and discuss Welcome and Introductions challenges and opportunities of how to deliver care in John J. Oppenheimer, MD, FACAAI and school-based settings. Brian T. Kelly, MD, MA, FACAAI Track: Food & Drug Allergy and GI Disorders It’s a Unified Airway: Options for Sinus Disease Anju T. Peters, MD 10:00 am Welcome and Introductions Current and Emerging Biologics in Atopic Dermatitis Bruce J. Lanser, MD, FACAAI, and Mark Boguniewicz, MD, FACAAI Irene Mikhail, MD Beyond OIT: How Biologics Can Help Patients With 10:03 am Improving the Health of Students: Food Allergy Successful Approaches to Community David M. Fleischer, MD, FACAAI Partnerships With Schools Michael Pistiner, MD, MMSc, FACAAI Adjourn 10:30 am Food Allergies and Anaphylaxis in Schools Julie Wang, MD, FACAAI 10:55 am Wheezing in the Classroom: School-based Asthma Management Sujani Kakumanu, MD 11:20 am Questions and Discussion 11:30 am Adjourn

LIVE RECORDED RECORDED+ 41 Saturday, November 14

10:00 – 11:30 am CST 10:00 – 11:30 am CST Joint ACAAI/WAO Presentation – Oral Abstracts – World Allergy Forum Angioedema/Urticaria Corticosteroid Stewardship in Moderator: Kelly M. Maples, MD, FACAAI Allergic Diseases 10:00 am Welcome and Introductions Moderators: Kelly M. Maples, MD, FACAAI ACAAI President J. Allen Meadows, MD, FACAAI, and WAO President Motohiro Ebisawa, MD 10:03 am Changes in Utilization of Acute Medications After Initiation of Prophylactic Treatments The evidence shows that there are consequences of for Hereditary Angioedema using oral corticosteroids (OCS) even in low doses. Dawn Hyatt, PharmD Overuse of OCS presents even more challenges up to, and including, mortality. Thus, there is a high cost 10:18 am The Food Sensitization Related to A-896G involved in OCS overuse due to side effects. Even Gene Polymorphism of TLR-4 in Adults With though biologics are expensive, they do offer an Atopic Dermatitis alternative to OCS. OCS overuse is relevant in GI and Yuriy Bisyuk, MD pulmonology as well as allergy. 10:33 am Friends Don’t Let Friends Mix Alone: Track: Asthma and Respiratory / Sleep Disorders Anaphylaxis in the Mixing Lab Mike Tankersley, MD, MBA, FACAAI Welcome and Introductions 10:48 am ACAAI President J. Allen Meadows, MD, FACAAI, and Questions and Discussion (Online Chat) WAO President Motohiro Ebisawa, MD 11:30 am Adjourn Effects of Corticosteroids on Human Health Eugene R. Bleecker, MD Health Consequences of Overuse of Corticosteroids Arnaud Bourdin, MD Economic Impacts – Cost of Side Effects From Overuse of Corticosteroids Giorgio Walter Canonica, MD Adjourn

LIVE RECORDED RECORDED+ 42 Saturday, November 14

10:00 – 11:30 am CST 10:00 – 11:00 am CST Joint ACAAI/AAAAI Session Advanced Practice Program Ensuring the Success of Clinical Pearls From Academic Allergy the Dermatologist Moderators: Bryan L. Martin, DO, FACAAI, and Moderator: Jodi A. Shroba, MSN, APRN, CPNP Aidan A. Long, MD While practicing in allergy, health care practitioners are This program is designed to bring together academic often asked about a rash or other skin conditions. This allergy/immunology leaders, including department/ session will improve their diagnosis and management division/section leaders, associate leaders and program skills for common skin conditions that may present in the directors, to hear about work that has been done by allergy office. the task force and to provide additional input into the Educational credit for the Advanced Practice Health task force deliberations. The overall effort is to create Care Providers Course is only available to those who pre- a viable and energetic network of academic allergy/ registered for it. immunology leaders who can ensure that the profession survives and thrives in the changing academic 10:00 am Welcome and Introductions environment. Jodi A. Shroba, MSN, APRN, CPNP Track: Practice Management / Professional Issues 10:03 am Clinical Pearls From the Dermatologist Marc Serota, MD Welcome and Introductions Bryan L. Martin, DO, FACAAI, and 10:45 am Questions and Discussion (Online Chat) Aidan A. Long, MD 11:00 am Adjourn Joint Task Force Update Bryan L. Martin, DO, FACAAI Increasing the Scope and Visibility of Your Academic Division 11:35 am – 12:30 pm CST Aidan A. Long, MD Industry Programs (See page 67 for details.) Overcoming Financial Issues in the Academic Allergy/ Immunology Division Kevin J. Kelly, MD, FACAAI Adjourn

LIVE RECORDED RECORDED+ 43 Saturday, November 14

1:00 – 2:30 pm CST 1:00 – 2:30 pm CST What’s That Rash? How to Discuss Complementary GAME Doctor, What’s Wrong and Alternative Medicine SHOW! With My Skin? With Patients and Implement Host: Stephanie L. Mawhirt, DO Into Practice This session is designed to assist the attendee in Moderators: William S. Silvers, MD, FACAAI, and developing a better understanding of terms used to Payel Gupta, MD, FACAAI diagnose various skin conditions, recognize common According to recent data from the NIH and Natural and similar patterns of skin disease and formulate a Center for Health Statistics, approximately 38% of treatment strategy. Rapid fire, high yield and fun, all rolled into one. adults and 12% of children use some form of integrative medicine, while more than 60% of allergy sufferers Track: Dermatology try a natural product. This has significant impact on Faculty: Kelly M. Maples, MD, FACAAI; the traditional practice of medicine. There is a need Luz S. Fonacier, MD, FACAAI, and James Treat, MD to improve our recognition and understanding of integrative medicine (“complementary and alternative”) 1:00 pm Welcome and Introductions therapies in the field of allergy and immunology. Stephanie L. Mawhirt, DO This session is designed as an introductory course to 1:05 pm Game Time! educate allergy and immunology specialists on the most 2:20 pm Questions and Discussion common integrative medicine therapies being used in our field. 2:30 pm Adjourn Track: Environmental and Integrative Medicine

1:00 – 2:30 pm CST 1:00 pm Welcome and Introductions William S. Silvers, MD, FACAAI, and The Not on Thursday Program: Payel Gupta, MD, FACAAI Cough – Part 2 1:03 pm Bringing It Into Your Practice Moderators: Alan B. Goldsobel, MD, FACAAI, and Anil Nanda, MD, FACAAI David R. Stukus, MD, FACAAI 1:30 pm Practical Tips Supported by an independent educational grant from Dipa K. Sheth, MD, FACAAI Merck 1:55 pm What Does the Evidence Support? 1:00 pm Welcome and Introductions Gary K. Soffer, MD Alan B. Goldsobel, MD, FACAAI, and 2:20 pm David R. Stukus, MD, FACAAI Questions and Discussion (Online Chat) 1:03 pm How Our Understanding of 2:30 pm Adjourn Pathophysiology Has Evolved Jaclyn Smith, MB, ChB, PhD 1:30 pm Current Guideline-based Approaches to Treatment of Cough Kaiser Lim, MD 1:55 pm Insight Into New Treatment Paradigms Peter Dicpinigaitis, MD 2:20 pm Questions and Discussion 2:30 pm Adjourn

LIVE RECORDED RECORDED+ 44 Saturday, November 14

1:00 – 2:30 pm CST 1:00 – 2:30 pm CST Oral Abstracts – Asthma/Rhinitis Continuous Assessment Program Moderator: J. Wesley Sublett, MD, MPH, FACAAI (CAP) Review – Session 1 Moderator: Brian T. Kelly, MD, MA, FACAAI 1:00 pm Welcome and Introductions J. Wesley Sublett, MD, MPH, FACAAI The CAP Review is a literature-style review covering most of the articles chosen by the ABAI for the current 1:03 pm Tezepelumab Efficacy in Severe Asthma by six-month cycle of the Continuous Assessment Program Specific Allergen Sensitivity: Results From (CAP). Each presenter will focus on key aspects of the the PATHWAY Study study design, results and implications for practice. The Jonathan Corren, MD, FACAAI goal of this session is to help prepare attendees for the 1:18 pm Eosinophilia (>300/ul) Marks Small first cycle of ABAI CAP program. Airway Obstruction Irrespective of Due to the impacts of COVID-19 on physicians, ABAI has Allergic Sensitization in Inner-city Severe canceled Block 2 for 2020. The completion of the Block 1 Asthmatics Continuous Assessment Program has been extended to Granit Mavraj, MD January 15, 2021. 1:33 pm Changes in Nasal Airflow With Loratadine- Track: Asthma and Respiratory / Sleep Disorders pseudoephedrine Versus Fluticasone Spray After First Dose for Allergy Welcome and Introductions Anne K. Ellis, MD, MSc, FACAAI Brian T. Kelly, MD, MA, FACAAI 1:48 pm Serum IL-6 Levels in Patients With Head/Neck Aspirin-exacerbated Respiratory Disease Jeremy Katcher, MD, FACAAI Anuj Kapil, MD Dermatologic 2:03 pm House Dust Mite Environmental Exposure Kelly M. Maples, MD, FACAAI Unit: Clinical Validation of a Model for Perennial Allergic Rhinitis Lung/Food & Drug Allergy/ Lubnaa Hossenbaccus Hypersensitivity Reactions Brian T. Kelly, MD, MA, FACAAI 2:18 pm Questions and Discussion (Online Chat) Adjourn 2:30 pm Adjourn

LIVE RECORDED RECORDED+ 45 Saturday, November 14

1:00 – 2:30 pm CST 3:00 – 4:30 pm CST Advanced Practice Program FIT Integrated Educational Program Food for Thought on Anaphylaxis & Business Meeting Moderator: Jodi A. Shroba, MSN, APRN, CPNP 3:00 pm Welcome and Introductions Idiopathic anaphylaxis can be frustrating and Miriam Samstein, MD, and challenging for both patients and clinicians. This session Timothy Chow, MD will explore the diagnosis and management of this 3:10 pm Junior FIT Representative Candidate condition along with the latest recommendations for Speeches & Voting management of anaphylaxis from any cause. 3:25 pm Career Panel Alpha-gal allergy is a delayed allergic reaction to the Angela Hogan, MD, FACAAI; ingestion of mammalian meats which contains the Anil Nanda, MD, FACAAI; and sugar or carbohydrate alpha gal (glactose-alpha-1, Stephen Tilles, MD, FACAAI 3-galactose). This allergy is triggered by a tick bite. This session will review the development and management of 4:25 pm Announcement of 2020-2021 Junior FIT this tick-borne allergy. Representative and Closing Remarks Educational credit for the Advanced Practice Health 4:30 pm Adjourn Care Providers Course is only available to those who pre- registered for it. 3:00 – 4:30 pm CST Welcome and Introductions The Not on Thursday Program: Jodi A. Shroba, MSN, APRN, CPNP Biologics Idiopathic Anaphylaxis and Updates on Anaphylaxis Management Moderators: John J. Oppenheimer, MD, FACAAI, and Julie Wang, MD, FACAAI Brian T. Kelly, MD, MA, FACAAI Just One Bite Can Cause a Food Allergy: A Review of Track: Immunotherapy and Diagnostics Alpha-gal 3:00 pm Scott Commins, MD, PhD Welcome and Introductions John J. Oppenheimer, MD, FACAAI, and Adjourn Brian T. Kelly, MD, MA, FACAAI 3:03 pm Navigating Current Asthma Choices Thomas B. Casale, MD, FACAAI

2:35 – 3:00 pm CST 3:45 pm Cost-effectiveness of Biologics Stanley J. Szefler, MD, FACAAI Industry Program (See page 68 for details.) 4:20 pm Questions and Discussion 4:30 pm Adjourn

LIVE RECORDED RECORDED+ 46 Saturday, November 14

3:00 – 4:30 pm CST 3:00 – 4:30 pm CST Beyond Antihistamines: “I’m Sorry Smokey, You Are Strategies for Relieving Over the Line!” The Case for Better Antihistamine-refractory Understanding of Allergenic Chronic Urticaria Thresholds and How This Can Moderators: Kelly M. Maples, MD, FACAAI, and Improve Patient Care Joseph P. Forester, DO, FACAAI Moderators: Douglas P. Mack, MD, MSc, and The management of chronic urticaria has evolved in Brian T. Kelly, MD, MA, FACAAI recent years, but several mainstays can continue to The concept of allergenic thresholds remains elusive and offer benefit. This session will review the evidence controversial. While there is evidence that these exist, surrounding older approaches, current approaches and there is also uncertainty in how these can be established what potential treatment options may be available. The and regulated and how they may vary at a patient level. important aspect of helping patients beyond medication Understanding of thresholds has broad social and and addressing the significant psychosocial impact of medico-legal impact with respect to how patients are refractory chronic urticaria will also be addressed. being managed and how products are labeled at stores Track: Dermatology and in restaurants. Track: Food & Drug Allergy and GI Disorders 3:00 pm Welcome and Introductions Kelly M. Maples, MD, FACAAI, and Welcome and Introductions Joseph P. Forester, DO, FACAAI Douglas P. Mack, MD, MSc, and 3:03 pm Omalizumab for Antihistamine-refractory Brian T. Kelly, MD, MA, FACAAI Urticaria Understanding Variability in Threshold Response Sarbjit S. Saini, MD Andrew Clark, MD 3:25 pm Emerging Therapies for Refractory Urticaria Understanding the Regulatory Climate for David A. Khan, MD, FACAAI Threshold Labeling 3:50 pm Evidence for Other Biologics in Stefano Luccioli, MD Refractory Urticaria The Australian Experience Regarding VITAL Marc Serota, MD Jennifer Koplin, MD, PhD 4:15 pm Questions and Discussion (Online Chat) Adjourn 4:30 pm Adjourn

LIVE RECORDED RECORDED+ 47 Saturday, November 14

3:00 – 4:30 pm CST 3:00 – 4:30 pm CST Continuous Assessment Program Oral Abstracts – (CAP) Review – Session 2 Allergy Diagnostics/Aerobiology/ Moderator: Brian T. Kelly, MD, MA, FACAAI Food Allergy The CAP Review is a literature-style review covering Moderator: Gerald B. Lee, MD most of the articles chosen by the ABAI for the current 3:00 pm Welcome and Introductions six-month cycle of the Continuous Assessment Program Gerald B. Lee, MD (CAP). Each presenter will focus on key aspects of the study design, results and implications for practice. The 3:03 pm Decoding Allergic Poly-sensitization With goal of this session is to help prepare attendees for the Machine Learning first cycle of ABAI CAP program. Brian Patchett 3:18 pm The Role of Aeroallergens in the Due to the impacts of COVID-19 on physicians, ABAI has Pathogenesis of Eosinophilic Esophagitis: canceled Block 2 for 2020. The completion of the Block 1 Is There a Relationship? Continuous Assessment Program has been extended to Talal Nsouli, MD, FACAAI (HON) January 15, 2021. 3:33 pm Specific Peanut Epitopes as a Biomarker Track: Practice Management / Professional Issues for Desensitization During Epicutaneous Immunotherapy Welcome and Introductions David M. Fleischer, MD, FACAAI Brian T. Kelly, MD, MA, FACAAI 3:48 pm Dietary Access and Behaviors Among Food Anaphylaxis Allergic Black and White Children in the Anne K. Ellis, MD, MSc, FACAAI FORWARD Study Amaziah Coleman, MD Immune Hypersensitivity Disorders Nikita Raje, MD, FACAAI 4:03 pm Questions and Discussion (Online Chat) Immunodeficiencies 4:30 pm Adjourn Benjamin Prince, MD Eosinophilic or Gastrointestinal Disorders Gerald B. Lee, MD 3:00 – 4:30 pm CST Adjourn Editor’s Pick – Best Articles from Annals of Allergy, SPECIAL TION Asthma and Immunology PRESENTA Moderator: John J. Oppenheimer, MD, FACAAI This session will highlight several of the best articles published in Annals. The current Editor-in-Chief of Annals, Gailen Marshall, Jr., MD, PhD, FACAAI, and Editor-in-Chief Elect, Mitchell Grayson, MD, FACAAI, will provide insight regarding the impact and clinical application of various articles pertaining to allergy and immunology. Speakers: Gailen D. Marshall, Jr., MD, PhD, FACAAI, and Mitchell H. Grayson, MD, FACAAI

LIVE RECORDED RECORDED+ 48 Saturday, November 14

3:00 – 4:30 pm CST 4:30 – 5:15 pm CST Advanced Practice Program ACAAI 2020 Psychosocial Management of Annual Business Meeting Food Allergy and Atopic Dermatitis All members are invited to attend. Learn about important College initiatives and help us recognize Moderator: Jodi A. Shroba, MSN, APRN, CPNP our 2020 award recipients. We’ll also welcome our new There is mounting evidence that children with allergic officers and regents. conditions – including food allergy, eosinophilic esophagitis (EoE), and atopic dermatitis – and their families experience psychosocial stressors such as poor 5:15 – 6:15 pm CST quality of life, stress, anxiety, depression, social challenges including bullying and low self-esteem. When examined 29th Annual FIT Bowl individually, unique challenges are noted for each Emcee: Bryan Martin, DO, FACAAI allergic condition due to the nature of the condition’s presentation and treatment regimen. The presenters Supported by DBV Technologies will describe the psychological intervention services Test your knowledge, sharpen your wits and join in the they provide and how mental health professionals are fun at this year’s virtual FIT Bowl! Watch participating integrated into clinics that treat these populations. teams from training programs around the country Educational credit for the Advanced Practice Health compete to answer a variety of questions posed by an Care Providers Course is only available to those who pre- expert panel. See page 13 for more information. registered for it.

3:00 pm Welcome and Introductions Jodi A. Shroba, MSN, APRN, CPNP 6:15 – 7:15 pm CST 3:03 pm The Clinical Role of Psychology in Food Industry Programs Allergy (See page 69 for details.) Ashley Ramos, PhD 3:25 pm Psychosocial Challenges in Pediatric Eosinophilic Esophagitis Ashley Kroon Van Diest, PhD 3:50 pm Assessing Emotional and Behavioral Health in Children and Adults With Atopic Dermatitis Jennifer Darr, MSW, LCSW 4:15 pm Questions and Discussion (Online Chat) 4:30 pm Adjourn

LIVE RECORDED RECORDED+ 49 Sunday, November 15

8:00 – 9:30 am CST 8:00 – 9:30 am CST How To Implement Updates SLIT Versus SCIT – From the Latest Clinical Guidelines Let the Battle Begin Into Practice Moderators: Myron J. Zitt, MD, FACAAI, and Moderator: Todd A. Mahr, MD, FACAAI Stanley M. Fineman, MD, MBA, FACAAI This plenary will include high-yield practical information Presently, there are two delivery options for from three recently updated practice parameters: immunotherapy available to treat respiratory allergy. Rhinitis, Anaphylaxis and Diagnostic Testing for Many allergists have difficulty in determining the optimal Peanut Allergy. Each speaker was intimately involved therapy for their patients. in the development of each guideline and can offer Track: Immunotherapy and Diagnostics unmatched perspective. This is a can’t-miss session applicable to all meeting attendees. 8:00 am Welcome and Introductions Myron J. Zitt, MD, FACAAI, and 8:00 am Welcome and Introductions Stanley M. Fineman, MD, MBA, FACAAI Todd A. Mahr, MD, FACAAI 8:03 am SCIT Is the Answer 8:03 am Practice Parameter – Rhinitis David I. Bernstein, MD, FACAAI Mark S. Dykewicz, MD, FACAAI 8:30 am SLIT Is the Answer 8:30 am Practice Parameter – Anaphylaxis Peter S. Creticos, MD Marcus S. Shaker, MD, FACAAI 8:55 am No One Option Is Perfect – A Role for 8:55 am Practice Parameter – Diagnostic Testing for Shared Decision-making Peanut Allergy Desiree E. Larenas-Linnemann, MD Matthew C. Greenhawt, MD, MBA, MSc, 9:20 am Questions and Discussion FACAAI 9:30 am Adjourn 9:20 am Questions and Discussion 9:30 am Adjourn

Time Zones All sessions are listed in Central Standard Time (CST). Don’t forget to convert them to your local time zone when planning your schedule!

LIVE RECORDED RECORDED+ 50 Sunday, November 15

8:00 – 9:30 am CST 8:00 – 9:30 am CST Separate registration required Itching to Help: Diagnosis Literature Review: and Management of Itch and Morning Program – Part 1 Dermatitis in Special Populations Moderator: James T. Li, MD, PhD, FACAAI Moderators: Ira Finegold, MD, FACAAI, and Ellen R. Sher, MD, FACAAI To help you stay abreast of the latest clinical developments in allergy and immunology, the College Conditions impacting the skin can change dramatically will continue its highly successful literature review in patients with different backgrounds. This session program. It’s a review of the most important, clinically- will review special populations and how evaluation focused literature of our specialty published between and treatment of dermatitis can be tailored based November 2019 and October 2020, with emphasis on on physiologic, socioeconomic and psychosocial clinical relevance. Faculty includes allergy/immunology differences. training program directors and specialists in practice. Track: Dermatology The Literature Review Program is only available to those who pre-registered for it. 8:00 am Welcome and Introductions Ira Finegold, MD, FACAAI, and Welcome and Introductions Ellen R. Sher, MD, FACAAI James T. Li, MD, PhD, FACAAI 8:03 am Itch and Dermatitis in the Elderly Basic Immunology David R. Weldon, MD, FACAAI Mitchell H. Grayson, MD, FACAAI 8:30 am Dermatitis in Skin of Color Rhinitis and Sinusitis Andrew Alexis, MD, MPH Anju T. Peters, MD 8:55 am Occupational Dermatitis Update in Clinical Immunology Karin A. Pacheco, MD, MSPH John M. Routes, MD, FACAAI 9:20 am Questions and Discussion (Online Chat) Adjourn 9:30 am Adjourn

LIVE RECORDED RECORDED+ 51 Sunday, November 15

8:00 – 9:00 am CST 8:00 – 9:00 am CST Building ABAI Continuing Oral Abstracts – Certification Together Clemens von Pirquet Awardees Moderators: Michael R. Nelson, MD, PhD, FACAAI, and Moderator: Brian T. Kelly, MD, MA, FACAAI Kathleen May, MD, FACAAI ACAAI is pleased to present our Clemens von Pirquet The ACAAI, ABAI and diplomates are key stakeholders Recipients for the 2020 Annual Meeting. in the current transformation of Allergy and Immunology Continuing Certification. This session will provide 8:00 am Welcome and Introductions attendees with an overview of the current landscape Brian T. Kelly, MD, MA, FACAAI of continuing board certification, an update of the 8:03 am Clemens von Pirquet – 1st Place Award continuous certification assessment program (CAP) Pulse Oximetry and Centile-based Vital and the personal progress meter. An interactive town Signs Predict Hospital Length of Stay in hall will be held during this session as part of ABAI’s Pediatric Asthma Exacerbation commitment to co-development of specialty continuing Jose Rojas Camayo, MD certification. 8:18 am Clemens von Pirquet – 2nd Place Award Practice Management / Professional Issues Track: Clinical Impact of Reported Non-steroidal Anti-inflammatory Drug Allergies in Welcome and Introductions Patients With Osteoarthritis Michael R. Nelson, MD, PhD, FACAAI, and Lily Li, MD Kathleen May, MD, FACAAI 8:33 am Clemens von Pirquet – 3rd Place Award Provide Understanding of Continuous Assessment Characterizing Asthma Among Adults With Program (CAP) Primary Antibody Deficiencies: Results Michael R. Nelson, MD, PhD, FACAAI From a Nationwide Patient Survey Understand the ABMS, ABAI Vision Commission and Deepti Deshpande, MD What It Means to You 8:48 am Questions and Discussions (Online Chat) Michael R. Nelson, MD, PhD, FACAAI 9:00 am Adjourn Understand Use of Diplomate Progress Meter

Kathleen May, MD, FACAAI Town Hall Q&A (Online Chat) Michael R. Nelson, MD, PhD, FACAAI; Kathleen May, MD, FACAAI; Ted Freeman, MD, FACAAI; Rayne Harrison and Cecelia MacCormack Adjourn

LIVE RECORDED RECORDED+ 52 Sunday, November 15

8:00 – 8:45 am CST 10:00 – 11:30 am CST Allied Health Professionals Program Coding and Government Relations The Role of the Nurse in the Moderators: James Sublett, MD, FACAAI, and Care and Management of Patients Warner W. Carr, MD, FACAAI With Atopic Dermatitis This session will address relevant changes, modifications and implementation of CPT and ICD-10 coding for Moderator: Abby L. Allen, RN, NP 2021. This will be accomplished by practical case-based Supported by an independent educational grant from scenarios focused on how the change may affect the Aimmune Therapeutics practice of allergy and clinical immunology. In addition, we’ll review the state of politics and the national This session will discuss the diagnosis and management perspective of medicine as seen through the eyes of of atopic dermatitis. It will also discuss the role that the AMA. Finally, we’ll offer an update on the changing allied health professionals play in providing emotional landscape on Capitol Hill as it relates to the current state support, formal and systematic education and of government. individualized practical advice that contributes to improved treatment adherence and can enhance the Track: Practice Management / Professional Issues quality of life for patients and their families throughout 10:00 am the course of an often-prolonged disease. Welcome and Introductions James L. Sublett, MD, FACAAI, and Educational credit for the Allied Health Professionals Warner W. Carr, MD, FACAAI Course is only available to those who pre-registered for it. 10:03 am Coding Update Welcome and Introductions Gary N. Gross, MD, FACAAI Abby L. Allen, RN, NP 10:28 am The Importance of the Physician Advocate The Role of the Nurse in the Care and Management of James M. Tracy, DO, FACAAI Patients With Atopic Dermatitis 10:53 am Government/Legislative Update Sally Schoessler, MSEd, BSN, RN, AE-C Bill Finerfrock, President, Capitol Associates; Adjourn Consultant, Advocacy Council of ACAAI 11:20 am Questions and Discussion 11:30 am Adjourn

LIVE RECORDED RECORDED+ 53 Sunday, November 15

10:00 – 11:30 am CST 10:00 – 11:30 am CST Caring for Patients Separate registration required Across Multiple Populations Literature Review: Moderators: Jeremy S. Katcher, MD, FACAAI, and Morning Program – Part 2 Jared Darveaux, MD Moderator: James T. Li, MD, PhD, FACAAI Supported in part by an independent educational grant To help you stay abreast of the latest clinical from AstraZeneca developments in allergy and immunology, the College The more we learn about asthma, the more we know it is will continue its highly successful literature review not a “one size fits all” condition. This session will review program. It’s a review of the most important, clinically- special populations and how their asthma care can be focused literature of our specialty published between tailored based on physiologic, socioeconomic, and November 2019 and October 2020, with emphasis on psychosocial differences. clinical relevance. Faculty includes allergy/immunology training program directors and specialists in practice. Track: Asthma and Respiratory / Sleep Disorders The Literature Review Program is only available to those 10:00 am Welcome and Introductions who pre-registered for it. Jeremy S. Katcher, MD, FACAAI, and Jared Darveaux, MD Welcome and Introductions James T. Li, MD, PhD, FACAAI 10:03 am Impact of Hormones and Pregnancy on Asthma and Allergies Asthma and Lower Respiratory Diseases Jennifer Namazy, MD James T. Li, MD, PhD, FACAAI 10:30 am Asthma, Rhinitis and Allergic Skin Disease Update on Skin Diseases, Urticaria, Angioedema and in Older Adults Other Skin Disorders Tolly E. Epstein, MD, MS, FACAAI Marc A. Riedl, MD, MS 10:55 am Racial and Ethnic Disparities in Asthma and Update in Pediatric Allergy Allergic Disease John M. Kelso, MD, FACAAI Andrea J. Apter, MD, FACAAI Adjourn 11:20 am Questions and Discussion 11:30 am Adjourn

LIVE RECORDED RECORDED+ 54 Sunday, November 15

10:00 – 11:30 am CST 10:00 – 11:30 am CST Marijuana, E-cigs, Vaping, EAACI – Allergen Immunotherapy Hookah and More: in 2020: Still a Valid Intervention? How To Discuss With Patients Moderators: Marek Jutel, MD, PhD, and Moderators: Ojas P. Patel, MD, FACAAI, and J. Allen Meadows, MD, FACAAI Andrew Nickels, MD, FACAAI The EAACI Symposium is dedicated to allergen The use of medical marijuana and its derivatives, immunotherapy as an essential tool for achieving long- electronic cigarettes, and alternative nicotine delivery term control of allergic diseases and asthma. systems is on the rise, yet the risks and health benefits Track: Immunotherapy and Diagnostics remain largely unclear. Furthermore, recent literature suggests that some of the more popular routes of Welcome and Introductions administration, including vaping and hookah, can have Marek Jutel, MD, PhD, and deleterious health effects. Due to a rise in use across J. Allen Meadows, MD, FACAAI various ages, allergy and immunology specialists need Barriers and Facilitators in Research and to understand how these agents are being used and Clinical Practice incorporate discussion of them into patient visits. Stefano del Giacco, MD, PhD Population Health and Infectious Diseases / Track: AIT for Allergic Asthma – Controversies and Solutions International Travel Ioana O. Agache, MD, PhD 10:00 am Welcome and Introductions Bridging the Gap: Innovative Methodology Ojas P. Patel, MD, FACAAI, and for AIT Trials Andrew Nickels, MD, FACAAI Marek Jutel, MD, PhD 10:03 am Making Sense of the Different Terminology Adjourn and Delivery Systems William S. Silvers, MD, FACAAI 10:30 am Risks, Benefits and Adverse Effects: What Does the Evidence Show? Rohit K. Katial, MD, FACAAI 10:55 am How To Effectively Discuss Use With Adolescent Patients Kevin R. Murphy, MD, FACAAI 11:20 am Questions and Discussion (Online Chat) 11:30 am Adjourn

LIVE RECORDED RECORDED+ 55 Sunday, November 15

10:00 – 11:30 am CST 10:00 – 11:30 am CST Oral Abstracts – Allied Health Professionals Program COVID-19/Quality Improvement Let’s Work Together: Moderator: Melanie A. Ruffner, MD, PhD Collaborative Patient Care Models in Community Allergy Practices 10:00 am Welcome and Introductions Melanie A. Ruffner, MD, PhD Moderator: Abby L. Allen, RN, NP 10:03 am Inner-city Asthma Telemedicine During Supported by an independent educational grant from COVID Pandemic Aimmune Therapeutics Kenny Kwong, MD Food allergies and other allergic conditions can have 10:18 am Long-term Efficacy of a Video Module a significant impact on quality of life, both medically on Resident and Medical Student and psychosocially. Therefore, a collaborative care Understanding of Penicillin Allergy model that includes partnering with allied healthcare Kavitha Thiagarajan, MD professionals can result in more robust patient care. Participants will be given information on multiple allied 10:33 am The Impact of COVID-19 and Disease healthcare fields, as well as the benefits, methods and Control Measures on Pediatric Food Allergy logistics of partnering with these providers. Parents/Caregivers and Patients Christopher Warren, MD Educational credit for the Allied Health Professionals Course is only available to those who pre-registered for it. 10:48 am A Quality Improvement Project on Pediatric Resident Knowledge of Primary Welcome and Introductions Immunodeficiency Abby L. Allen, RN, NP Yatyng Chang, MD Let’s Work Together: Collaborative Patient Care 11:03 am Expanding Penicillin Allergy Evaluation for Models in Community Allergy Practices Prenatal Patients J. Wesley Sublett, MD, MPH, FACAAI; Lulu Tsao, MD Raquel Durban, MS, RD, CSP, LDN; 11:18 am Questions and Discussion (Online Chat) Tamara Hubbard, MA, LCPC; and Linda Herbert, PhD 11:30 am Adjourn Adjourn

11:35 am – 12:30 pm CST Industry Programs (See page 70 for details.)

LIVE RECORDED RECORDED+ 56 Sunday, November 15

1:00 – 2:30 pm CST 1:00 – 2:30 pm CST Masqueraders of The AAAAI/ACAAI/CSACI Common Allergic Conditions North American Food Allergy Moderators: Eric Yen, MD, and Prevention Guidelines Melanie A. Ruffner, MD, PhD Moderators: Susan Waserman, MD, FACAAI, and Allergists/immunologists often see referrals for Aikaterini Anagnostou, MD, PhD, FACAAI evaluation of patients who have a clinical history and/ In the wake of the multiple early introduction trials and or laboratory results that overlap between allergies a host of international guidelines and meta-analyses and other systemic conditions. This session will offer that have been published in the past 5 years, the practical tips on how to navigate the differential three North American allergy societies have jointly diagnosis and evaluation of patients who lack clear developed a set of comprehensive recommendations diagnoses. outlining an approach to the prevention of IgE- Track: Clinical Immunology and Autoimmune and mediated food allergy, which update the respective Biologicals society recommendations that predated these new developments. This session will inform the 1:00 pm Welcome and Introductions clinician regarding the new developments and the Eric Yen, MD, and recommended evidence-based approach that balances Melanie A. Ruffner, MD, PhD both cutting-edge scientific advances and practical 1:03 pm Elevated Total IgE Levels: What Can It Mean implementation of these recommendations. and When To Worry? Track: Food & Drug Allergy and GI Disorders Alexandra Freeman, MD 1:00 pm Welcome and Introductions 1:30 pm Evaluating a Patient With Elevated Susan Waserman, MD, FACAAI, and Peripheral Eosinophilia Aikaterini Anagnostou, MD, PhD, FACAAI Princess Ogbogu, MD, FACAAI 1:03 pm What’s New? Changes and Updates in 1:55 pm Autoimmune and Inflammatory Mimickers Prevention Recommendations Jennifer R. Heimall, MD Elissa M. Abrams, MD 2:20 pm Questions and Discussion 1:30 pm Policy Implications of the Updated 2:30 pm Adjourn Recommendations Marcus S. Shaker, MD, MSc, FACAAI 1:55 pm Lessons Learned From Widespread Implementation of Prevention Guidelines Kirsten Perrett, MD 2:20 pm Questions and Discussion 2:30 pm Adjourn

LIVE RECORDED RECORDED+ 57 Sunday, November 15

1:00 – 2:30 pm CST 1:00 – 2:30 pm CST Separate registration required The Influence of Social Media Literature Review: on Patients and Medical Afternoon Program – Part 1 Decision Making Moderator: David A. Khan, MD, FACAAI Moderator: Brian T. Kelly, MD, MA, FACAAI To help you stay abreast of the latest clinical A targeted look deep down the rabbit hole of biases, developments in allergy and immunology, the College conspiracies and echo chambers during the COVID-19 will continue its highly successful literature review pandemic. program. It’s a review of the most important, clinically- Track: Population Health and Infectious Diseases / focused literature of our specialty published between International Travel November 2019 and October 2020, with emphasis on clinical relevance. Faculty includes allergy/immunology 1:00 pm Welcome and Introduction training program directors and specialists in practice. Brian T. Kelly, MD, MA, FACAAI The Literature Review Program is only available to those 1:03 pm The Influence of Social Media on Patients who pre-registered for it. and Medical Decision-making David R. Stukus, MD, FACAAI Welcome and Introductions David A. Khan, MD, FACAAI 2:03 pm Questions and Discussion (Online Chat) Anaphylaxis and Stinging Insect Hypersensitivity 2:30 pm Adjourn Anne K. Ellis, MD, MSc, FACAAI Immunotherapy Harold S. Nelson, MD, FACAAI Food Allergy Matthew C. Greenhawt, MD, MSc, MBA, FACAAI Adjourn

LIVE RECORDED RECORDED+ 58 Sunday, November 15

1:00 – 2:30 pm CST 1:00 – 2:30 pm CST Oral Abstracts – Food Allergy Allied Health Professionals Program Moderator: Aikaterini Anagnostou, MD, PhD, FACAAI Oral Challenge Update Moderator: Abby L. Allen, RN, NP 1:00 pm Welcome and Introductions Aikaterini Anagnostou, MD, PhD, FACAAI Supported by an independent educational grant from Aimmune Therapeutics 1:03 pm Phenotypic Differences in Allergy to Multiple Foods Within a Cohort of Black Oral challenges are an essential part of food allergy and White Children management. This session will review how to Christopher Warren, PhD successfully perform oral challenges in the office and how to integrate the updated guidelines into your 1:18 pm Race/Ethnicity and Socioeconomic Status practice. Effect on Food Allergy-related Quality of Life in Children and Caregivers Educational credit for the Allied Health Professionals Christine Rubeiz, MD Course is only available to those who pre-registered for it.

1:33 pm Tree Nut Graded Oral Food Challenge 1:00 pm Welcome and Introductions Outcomes in a Pediatric Tertiary Care Abby L. Allen, RN, NP Center Melissa Anderson, MD 1:03 pm Oral Food Challenge Update J. Andrew Bird, MD, FACAAI 1:48 pm Barriers to Oral Food Challenges: A Qualitative Analysis of the Caregiver 1:25 pm In-office Challenges: Conducting Oral Perspective Food Challenges Natasha Correa, MD Maria Crain, APRN, CPNP 2:03 pm Food Allergy-related Bullying and School 1:50 pm Oral Challenge Updates: Considerations Policy Among Black and White Children in From a Dietitian the FORWARD Study Raquel Durban, MS, RD, CSP, LDN Dannielle Brown, MD 2:15 pm Questions and Discussion (Online Chat) 2:18 pm Questions and Discussion (Online Chat) 2:30 pm Adjourn 2:30 pm Adjourn

LIVE RECORDED RECORDED+ 59 Sunday, November 15

3:00 – 4:30 pm CST 3:00 – 4:30 pm CST GINA Versus NHLBI Asthma The Challenges of Severe Guidelines: How Do We Conjunctival Inflammation Reconcile Differences? Moderators: Jonathan M. Rodrigues, MD, FACAAI, and Moderators: James M. Quinn, MD, FACAAI, and Purvi S. Parikh, MD, FACAAI Anthony J. Bonitatibus, MD Treatment of the inflamed eye can present significant The updated 2019 GINA Guidelines represent a major challenges in the clinical setting, especially when shift in the strategy of treating mild asthma. Though multiple conditions may be present at the same there is potential long-term benefit to the patient, there time. Current scientific information about the are challenges in the adoption of these guidelines. pathophysiology, diagnosis and management of dry eye This session will review the benefits and challenges of syndrome and allergic eye conditions will be presented. these guidelines in the context of patient care, provider The attendees will subsequently be empowered to adherence, the pharmaceutical industry and regulatory improve patient outcomes. (FDA) issues. Track: Rhinitis / Sinusitis / Ocular and Anaphylaxis Track: Asthma and Respiratory / Sleep Disorders 3:00 pm Welcome and Introductions Jonathan M. Rodrigues, MD, FACAAI, and 3:00 pm Welcome and Introductions James M. Quinn, MD, FACAAI, and Purvi S. Parikh, MD, FACAAI Anthony J. Bonitatibus, MD 3:03 pm Pathophysiology of Dry Eye Syndrome and 3:03 pm Where Do They Overlap? Allergic Ocular Conditions Jonathan A. Bernstein, MD, FACAAI Merin E. Kuruvilla, MD 3:30 pm 3:30 pm Where Do They Differ? Diagnostic Evaluation of the Inflamed Eye Angela D. Hogan, MD, FACAAI Guillermo Amescua, MD 3:55 pm 3:55 pm What Are They Both Missing? Treatment of Dry Eye Syndrome and Leonard B. Bacharier, MD, FACAAI Allergic Ocular Conditions Leonard Bielory, MD, FACAAI 4:20 pm Questions and Discussion 4:20 pm Questions and Discussion 4:30 pm Adjourn 4:30 pm Adjourn

LIVE RECORDED RECORDED+ 60 Sunday, November 15

3:00 – 4:30 pm CST 3:00 – 4:30 pm CST Separate registration required Microbiome Across the Spectrum Literature Review: of Allergic Conditions Afternoon Program – Part 2 Moderators: Christina E. Ciaccio, MD, MSc, FACAAI, and Moderator: David A. Khan, MD, FACAAI Mitchell H. Grayson, MD, FACAAI To help you stay abreast of the latest clinical The microbiome is a hot topic and evidence surrounding developments in allergy and immunology, the College its association with various allergic conditions is rapidly will continue its highly successful literature review accumulating. This session will review the supportive program. It’s a review of the most important, clinically- evidence, practical approaches we can take now with focused literature of our specialty published between our patients and unanswered questions that surround November 2019 and October 2020, with emphasis on how the microbiome impacts common allergic clinical relevance. Faculty includes allergy/immunology conditions. training program directors and specialists in practice. Track: Clinical Immunology and Autoimmune The Literature Review Program is only available to those and Biologicals who pre-registered for it. Welcome and Introductions Christina E. Ciaccio, MD, MSc, FACAAI, and Welcome and Introductions David A. Khan, MD, FACAAI Mitchell H. Grayson, MD, FACAAI Occupational and Environmental Allergy The Impact of the Microbiome on Atopic Dermatitis Mark S. Dykewicz, MD, FACAAI Richard Gallo, MD Drug Allergy Respiratory Microbiome and Its Effect on Asthma Aleena Banerji, MD Christina E. Ciaccio, MD, MSc, FACAAI The Year’s Best Articles Alterations in the Microbiome in Patients With David A. Khan, MD, FACAAI Food Allergies Carina Venter, PhD, RD Adjourn Adjourn

LIVE RECORDED RECORDED+ 61 Sunday, November 15

3:00 – 4:30 pm CST 3:00 – 4:30 pm CST Hereditary Angioedema: Allied Health Professionals Program Rising to the Challenge Food Allergy Mimickers: Moderators: William R. Lumry, MD, FACAAI, and Non-IgE Food Intolerances Amar Dixit, MD Moderator: Abby L. Allen, RN, NP Hereditary angioedema (HAE) remains a condition Supported by an independent educational grant from with significant morbidity. In recent years, multiple Aimmune Therapeutics new therapeutic options have been developed, with additional ones in the pipeline. This session will compare This session will review how to differentiate IgE from the WAO HAE guidelines with the US HAE guidelines non-IgE food conditions with appropriate testing. and differentiate between intravenous C1 inhibitor, Once a diagnosis has been formulated, this session subcutaneous C1 inhibitor and the monoclonal antibody will review management of the condition, including the lanadelumab. In addition, future therapeutic options for implementation of nutritional recommendations. HAE will be reviewed. Educational credit for the Allied Health Professionals Track: Dermatology Course is only available to those who pre-registered for it.

3:00 pm Welcome and Introductions 3:00 pm Welcome and Introductions William R. Lumry, MD, FACAAI, and Abby L. Allen, RN, NP Amar Dixit, MD 3:03 pm Food Allergy Mimickers: Non-IgE Food 3:03 pm Comparing WAO Hereditary Angioedema Intolerances and US Hereditary Angioedema Guidelines Ashlee Law, PA-C Timothy J. Craig, DO, FACAAI 3:25 pm Food Allergy Mimickers: A Dietitian’s 3:30 pm How To Choose From the Current Therapies Vantage Point Aleena Banerji, MD Raquel Durban, MS, RD, CSP, LDN 3:55 pm What Does the Future Hold for Hereditary 3:50 pm Food Allergy Mimickers: Non-IgE Food Angioedema Therapy? Intolerances Marc A. Riedl, MD, MS Abby L. Allen, RN, NP 4:20 pm Questions and Discussion (Online Chat) 4:15 pm Questions and Discussion (Online Chat) 4:30 pm Adjourn 4:30 pm Adjourn

4:30 pm CST Annual Scientific Meeting Adjourns Thank you for joining us! Be safe.

LIVE RECORDED RECORDED+ 62 E-posters

Supported by Sanofi Genzyme and Regeneron Electronic posters are a vital part of your meeting experience. The posters and presentation schedule are searchable and accessible 24/7 online at college.acaai.org/eposters. New for 2020! E-posters will be accompanied by an audio/video presentation delivered by the presenting author. Two categories of e-posters are included. Scientific Research e-posters feature new studies and research in the field of allergy/immunology. Medically Challenging Case e-posters highlight the management of novel or very uncommon diseases, the unusual presentation of a disease or something unusual masquerading as common. E-posters will be available for viewing online beginning November 13 and remain available through August 2021.

LIVE RECORDED RECORDED+ 63 Industry Programs – Friday Available in the Auditorium of the Virtual Annual Meeting

These are non-CME offerings.

Friday, November 13 • 9:35 – 10:00 am

Type 2 Inflammation in Asthma Presented by: Todd Mahr, MD During this case-based presentation, an expert will review the role of Type 2 inflammation in asthma. Supported by Sanofi Genzyme and Regeneron

Friday, November 13 • 11:35 am – 12:30 pm

PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] From Evidence to Practice: The First FDA-Approved Treatment for Peanut Allergy Presented by: Dareen Siri, MD and Ananth Thyagarajan, MD Peanut allergy can significantly impact patients’ lives. With PALFORZIA now available, you can provide your patients with the first FDA-approved treatment for peanut allergy. Please join Dareen Siri, MD and Ananth Thyagarajan, MD as they review the clinical safety and efficacy of PALFORZIA and share their treatment experience. Supported by Aimmune Therapeutics

Investigating the Role of Eosinophils in Health, Airway Disease, and Hypereosinophilic Disorders Presented by: Charlene Prazma, PhD, Chair; Steven J. Ackerman, PhD; Jonathan Corren, MD; and Princess Ogbogu, MD Eosinophils are well recognized as having important roles in immune-mediated disorders. Our program will review the immunomodulatory role of eosinophils in health and disease and their involvement in severe asthma (and potential co-morbidities) and hypereosinophilic disorders. The importance of biomarkers in the evaluation of eosinophilic disorders will also be highlighted. Supported by GSK

Rediscover Prevention: Proven Efficacy for Patients With HAE Presented by: Marc Riedl, MD and Andrea, Patient Ambassador Rediscover prevention in this dynamic program featuring data that shows what attack prevention can mean for your patients with HAE. Expert faculty will guide you through clinical data, including our new open-label extension study data, and a patient ambassador will bring the data to life by sharing her individual treatment experience. Supported by Takeda Pharmaceutical Company Limited

LIVE RECORDED RECORDED+ 64 Industry Programs – Friday Available in the Auditorium of the Virtual Annual Meeting

These are non-CME offerings.

Friday, November 13 • 2:35 – 3:00 pm

Understanding Nasal Polyposis Presented by: Tara F. Carr, MD A non-CME, disease state presentation focusing on nasal polyposis. Topics include: characteristics of nasal polyps, pathophysiology, common comorbid conditions, the role of type 2 inflammation in nasal polyposis, and the importance of an integrated multidisciplinary approach for optimal management. Supported by Novartis Pharmaceuticals Corporation

Type 2 Inflammation Presented by: Ujwala Kaza, MD During this case-based presentation, an expert will review the role of Type 2 inflammation in asthma, chronic rhinosinusitis with nasal polyposis, and atopic dermatitis. Supported by Sanofi Genzyme and Regeneron

Friday, November 13 • 5:30 – 6:30 pm

TSLP: A Key Epithelial Cytokine at the Top of the Asthma Inflammatory Cascade Presented by: Neal Jain, MD; Jonathan Corren, MD; and Anju Peters, MD Is there a novel way to think about asthma inflammation? Join a panel of leading experts to discuss 1) the central role of the airway epithelium and epithelial cytokines (alarmins) in asthma, and 2) the role of thymic stromal lymphopoietin (TSLP) as a key driver of multiple types of inflammation. Supported by AstraZeneca and Amgen

A Focus on Type 2 Inflammation in Asthma Presented by: William W. Busse, MD and Samuel Louie, MD Hear experts review Type 2 inflammation as a broad, underlying disease process. Our experts will review current literature on Type 2 cytokines, including IL-4 and IL-13, which contribute to epithelial barrier dysfunction, eosinophilic inflammation, and allergic inflammation. Supported by Sanofi Genzyme and Regeneron

Friday, November 13 at 5:30 – 6:30 pm continues on next page.

LIVE RECORDED RECORDED+ 65 Industry Programs – Friday Available in the Auditorium of the Virtual Annual Meeting

These are non-CME offerings.

Friday, November 13 • 5:30 – 6:30 pm

See EoE: A Closer Look at Diagnosing and Managing Eosinophilic Esophagitis Presented by: Jonathan Spergel, MD, PhD and Ikuo Hirano, MD Join our multidisciplinary speakers as they walk us through their perspectives of the most recent diagnostic and management guidelines for Eosinophilic Esophagitis. Together they will define EoE, describe various manifestations of chronic esophageal inflammation, and explore diagnostic challenges and management approaches in the context of guideline recommendations. Supported by Takeda Pharmaceuticals U.S.A., Inc.

Industry Programs – Saturday

Saturday, November 14 • 7:00 – 7:55 am

Systemic Mastocytosis: An Allergist/Immunologist Perspective on Diagnosis and Treatment Presented by: Mariana Castells, MD, PhD Supported by Blueprint Medicines

Saturday, November 14 • 9:35 – 10:00 am

Managing Food Allergy During the COVID-19 Pandemic and Implications for the Future Presented by: Matthew Greenhawt, MD The COVID-19 pandemic has revealed the importance of flexible approaches to caring for food-allergic patients, with potential implications for future treatment preferences. This symposium will include a discussion of the recent expert panel consensus document to guide decision-making in the allergy/ immunology clinic, with a focus on food allergy care. Supported by DBV Technologies

Saturday, November 14 at 9:35 – 10:00 am continues on next page.

LIVE RECORDED RECORDED+ 66 Industry Programs – Saturday Available in the Auditorium of the Virtual Annual Meeting

These are non-CME offerings.

Saturday, November 14 • 9:35 – 10:00 am

Understanding the Needs of Infants and Toddlers With Life-Threatening Allergies Presented by: Ruchi Gupta, MD and Todd Mahr, MD A discussion about the rising rates of anaphylaxis and the role providers play to help reduce the risk that a child will develop certain food allergies by identifying high-risk patients and educating caregivers on the early introduction of allergens. Dr. Gupta and Dr. Mahr are paid advisors for kaléo, Inc. Supported by by kaléo

Saturday, November 14 • 11:35 am – 12:30 pm

Targeting a Common Contributor to Severe Asthma Presented by: Katharine Woessner, MD You are cordially invited to view a pre-recorded program to learn about the clinical impact of a targeted biologic treatment option on exacerbations, lung function, and reducing oral corticosteroids in patients with severe eosinophilic asthma. Listen to an expert to explore its clinical efficacy, mechanism of action, and safety profile data. Supported by AstraZeneca

A Treatment Option for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months and Older Presented by: Adelaide A. Hebert, MD Join us for an interactive presentation on a steroid-free topical therapy for the treatment of mild-to- moderate atopic dermatitis. Expert faculty will guide the audience through an in-depth look into the product and answer questions to help attendees gain a better understanding of this treatment option. Supported by Pfizer, Inc.

Saturday, November 14 at 11:35 am – 12:30 pm continues on next page.

LIVE RECORDED RECORDED+ 67 Industry Programs – Saturday Available in the Auditorium of the Virtual Annual Meeting

These are non-CME offerings.

Saturday, November 14 • 11:35 am – 12:30 pm

The Role of Digitally Connected Inhalers: An Introduction to Digihaler® Technology Presented by: Greg Bensch, MD Please join us on November 14th at 11:35 am as Greg Bensch, MD presents Digihaler® Technology. Learn about the role of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder, ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder and AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder in clinical practice. Supported by Teva Pharmaceuticals, Inc.

Saturday, November 14 • 2:35 – 3:00 pm

Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease Presented by: David Bernstein, MD Hypereosinophilic syndrome (HES) is a rare and debilitating multi-system disorder characterized by elevated eosinophil levels in blood and/or tissues with organ damage/dysfunction that occurs without evidence of secondary causes of hypereosinophilia. Multiple organ involvement results in highly variable clinical manifestations. This brief presentation will provide a summary of current understanding. Supported by GSK

LIVE RECORDED RECORDED+ 68 Industry Programs – Saturday Available in the Auditorium of the Virtual Annual Meeting

These are non-CME offerings.

Saturday, November 14 • 6:15 – 7:15 pm

Disrupting Decades of Unmet Need: Targeting Uncontrolled Asthma & SABA Reliance With PRECISION Presented by: Bradley Chipps, MD; Miguel Lanz, MD; and Kevin Murphy, MD Join us to discuss real-world evidence updates on the relationships of asthma control, patient behaviors and SABA reliance as we focus on the unmet need in asthma patients who may be at risk for exacerbations. Learn how PRECISION may help improve the identification and management of patients with uncontrolled asthma. Supported by AstraZeneca

The Journey Towards Controlled Asthma: Shifting the Treatment Paradigm Presented by: John Oppenheimer, MD and Angela Hogan, MD Uncontrolled asthma continues to burden patients, care teams, and healthcare systems. Medical experts will provide insight into the challenges of coping with uncontrolled asthma, review the current treatment paradigms, and identify ways to customize management of uncontrolled asthma by pairing the right medications with the right patients. Supported by GSK

Keeping the Cat: A Transformational Approach to Reducing Fel d 1 Through the Cat’s Diet Presented by: Ebenezer Satyaraj, PhD This presentation provides an in-depth look at a proven innovation to neutralize Fel d 1, the major cat allergen, at its source. As part of a comprehensive allergen management program, this approach is safe for the cat and helps keep the cat in the home. Supported by Purina Institute

LIVE RECORDED RECORDED+ 69 Industry Programs – Sunday Available in the Auditorium of the Virtual Annual Meeting

These are non-CME offerings.

Sunday, November 15 • 11:35 am – 12:30 pm

Eosinophilic Immune Dysfunction Presented by: Rohit Katial, MD Join us for a presentation that will provide an overview of eosinophilic immune dysfunction, which can be characterized as the dysregulation of biological mechanisms involved with eosinophil recruitment and activation that is seen across a range of diseases. Supported by AstraZeneca

Clinical and Real-World Evidence for Using a Biologic to Treat Severe Eosinophilic Asthma Presented by: Jacqueline Eghrari-Sabet, MD This expert-led event will include a review and discussion of clinical and real-world data evaluating a biologic treatment to help reduce exacerbations and maintenance OCS use, as well as long-term clinical efficacy and safety data associated with the product. Supported by GSK

Deepening Our Understanding: Cytokine Signaling and the JAK/STAT Pathway in Atopic Dermatitis Presented by: Lee S. Clore Jr, MD During this presentation, Dr. Clore will review the disease state and burden of atopic dermatitis (AD), discuss the integral components in the pathophysiology of AD, and describe the role of the JAK/STAT pathway in AD. Supported by Pfizer, Inc.

LIVE RECORDED RECORDED+ 70 Exhibits

The virtual exhibit hall opens at 9:30 am CST on Friday, November 13. The College appreciates the support of its exhibitors and urges all attendees to visit over 40 virtual booths in the exhibit hall. Chat with industry representatives during meeting hours, or drop in anytime to view exhibits. Plus, collect tokens for the Leaderboard Contest to qualify to win great prizes! Also visit the College and Foundation booths to learn about resources and opportunities to engage. Exhibits will remain viewable through February 6, 2021 following the Annual Meeting.

ADMA Biologics 465 New Jersey 17 S Gold Partner Ramsey, NJ 07446 Phone: (201) 478-5552 Website: admabiologics.com Aimmune Therapeutics Contact Name: Michael Least 8000 Marina Blvd Contact Email: [email protected] 3rd Floor Brisbane, CA 94005 ADMA Biologics is an end-to-end commercial Phone: (408) 886-8984 biopharmaceutical company committed to Website: www.aimmune.com manufacturing, marketing and developing specialty Contact Name: Jennifer Kirchner Contact Email: [email protected] plasma-derived products for the prevention and treatment of infectious diseases in the immune Aimmune Therapeutics, Inc. is a biopharmaceutical compromised and other patients at risk for infection. company developing and commercializing treatments Our devotion to these underserved populations fuels for patients with food allergies. Aimmune was us, and our hands-on approach to production and formed by leading food allergy stakeholders who development sets us apart. concluded that a standardized oral immunotherapy approach was needed and that associated therapies needed to be developed. To deliver on that purpose, Silver Partner Aimmunedeveloped the Characterized Oral Desensitization ImmunoTherapy (CODIT®) approach, ALK-Abelló, Inc which is intended to mitigate allergic reactions from 1700 Royston Ln accidental exposure to food allergens. Aimmune isthe Round Rock, TX 78664 first company to have an FDA-approved treatment for Phone: (908) 842-8359 any food allergy and is applying the CODIT approach Website: www.alk.net/us to investigate additional food allergy therapies. Contact Name: Paul Ulrich Contact Email: [email protected] Please visit www.aimmune.com. The world leader in allergy immunotherapy (AIT), ALK is devoted to improving the quality of life for people with allergies by offering more convenient methods of administration, and thereby expanding the overall use of AIT to more patients. We are committed to broadening our presence in allergy care and will continue to innovate, develop and market new solutions beyond AIT, that bring us closer to allergic patients. Our goal is to build an effective future growth platform to engage with allergic patients and connect them with allergy specialists earlier in the disease progression.

LIVE RECORDED RECORDED+ 71 Exhibits

Allergists’ Foundation 85 W Algonquin Rd Platinum Partner Suite 550 Arlington Heights, IL 60005 Amgen/AstraZeneca Phone: (847) 725-2299 1800 Concord Pike Website: college.acaai.org/foundation Wilmington, DE 19850-5437 Contact Name: Miriam Standish Phone: (302) 885-2677 Contact Email: [email protected] Website: www.astrazeneca-us.com The College’s Foundation, now named the Allergists’ Contact Name: Brendan McEvoy Contact Email: [email protected] Foundation, has taken a new direction in its programming to focus more keenly on the needs of Amgen and AstraZeneca have partnered together practicing community allergists. Stop by the Foundation to bring new and innovative science to an area booth in the virtual exhibit hall to learn more and get where there remains a significant unmet need. The information on how you can apply for a grant and/or partnership leverages both companies’ respective support these efforts. capabilities including AstraZeneca’s extensive respiratory experience and Amgen’s deep history in Altus Biologics inflammatory diseases and bringing novel therapies 11233 Shadowcreek Pkwy to patients. Visit our Virtual Booth Experience to Suite 303 investigate the connection between TSLP, the Pearland, TX 77584 epithelium and severe asthma inflammation. Phone: (845) 518-4382 Website: www.altusbiologics.com/blog Contact Name: Jeraldin Fandino Contact Email: [email protected]

Altus Biologics is a biologics management organization. Platinum Partner We partner with physicians across multiple specialties to provide comprehensive, in-office infusion and subcutaneous injection services, allowing the physician AstraZeneca Pharmaceuticals, LP to have full oversight of patient treatment. At Altus 1800 Concord Pike Wilmington, DE 19850-5437 Biologics, we are committed to improving access, Phone: (302) 885-2677 quality of care and affordability for all patients. We stand Website: www.astrazeneca-us.com by our motto, “Treat each patient like family.” Contact Name: Brendan McEvoy Contact Email: [email protected] AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – oncology, cardiovascular & metabolic diseases and respiratory. The company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

LIVE RECORDED RECORDED+ 72 Exhibits

BioCryst Pharmaceuticals, Inc. CSL Behring 4505 Emperor Blvd 1020 First Ave Suite 200 King Of Prussia, PA 19406 Durham, NC 27703 Phone: (610) 878-4682 Phone: (919) 270-1275 Website: https;//www.cslbehring.com Website: www.biocryst.com Contact Name: Sophia Yu Contact Name: Kavita Aggarwal Contact Email: [email protected] CSL Behring is a global biotherapeutics leader driven Contact Name: Frank Nazzario by our promise to save lives. We meet patients’ Contact Email: [email protected] needs using the latest technologies to develop and BioCryst is a biotech company headquartered in deliver innovative therapies. The company offers a Durham, North Carolina with a Discovery Center of broad range of products in the industry for treating Excellence in Birmingham, Alabama. We discover novel, coagulation disorders, primary immune deficiencies, oral, small-molecule medicines that treat rare diseases hereditary angioedema, respiratory disease and chronic in which significant unmet medical needs exist and an inflammatory demyelinating polyneuropathy (CIDP). enzyme plays a key role in the biological pathway of the CSL Behring’s products are also used in cardiac surgery, disease. burn treatment and to prevent hemolytic disease of the newborn. At BioCryst, we are committed to delivering extraordinary medicines that empower patients to live For more information visit www.cslbehring.com and ordinary lives. We are passionate about developing follow us on Twitter @CSLBehring. and advancing novel medicines with a focus on oral therapies for people with rare and serious diseases to College Booth help them take part in the everyday activities they enjoy. 85 W Algonquin Rd Suite 550 Arlington Heights, IL 60005 Blueprint Medicines Phone: (847) 725-2285 45 Sidney St Website: college.acaai.org Cambridge, MA 02139 Contact Name: Gina Steiner Phone: (203) 376-1008 Contact Email: [email protected] Website: www.blueprintmedicines.com Contact Name: Lisa Young Visit the College booth to find out how the College Contact Email: [email protected] provides the support you need. Get connected and learn more about ongoing College programs, resources, Blueprint Medicines is a precision therapy company advocacy and more. striving to improve human health. With a focus on genomically-defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We have two FDA-approved precision therapies and are currently advancing multiple investigational medicines in clinical development, along with a number of research programs

LIVE RECORDED RECORDED+ 73 Exhibits

emocha Mobile Health Inc. Gold Partner 916 N Charles St 2nd Floor, Suite 200 DBV Technologies Baltimore, MD 21201 Phone: (410) 864-8587 25 Deforest Ave Website: www.emocha.com Summit, NJ 07901 Contact Name: Amy Cummings Website: www.dbv-technologies.com Contact Email: [email protected] DBV Technologies is developing Viaskin™, an emocha is the first comprehensive digital medication investigational proprietary technology adherence program, using asynchronous video check- platform with broad potential applications in ins and scalable human engagement to help patients immunotherapy. Viaskin is based on epicutaneous with asthma, tuberculosis, diabetes and transplant immunotherapy, or EPIT™, DBV’s method of recipients radically improve medication adherence. delivering biologically active compounds to the emocha remotely engages and supports patients with immune system through intact skin. With this new asthma while helping them improve non-adherence class of non-invasive product candidates, the and inhaler technique, resulting in better quality company is dedicated to safely transforming the care of life, improved clinical metrics and decreased of food allergic patients. DBV Technologies has global hospital utilization. emocha’s platform is used by headquarters in Montrouge, France and offices in health departments, hospitals and managed care Bagneux, France, and North American operations in organizations, with more than 120 customers across the Summit, NJ and New York, NY. globe serving over 50,000 patients..

Food Allergy & Anaphylaxis Connection Team (FAACT) Elsevier PO Box 511 1600 John F Kennedy Blvd West Chester, OH 45071 Suite 1600 Phone: (815) 276-3015 Philadelphia, PA 19103 Website: www.FoodAllergyAwareness.org Phone: (949) 929-4717 Contact Name: Eleanor Garrow-Holding Website: www.us.elsevierhealth.com Contact Email: [email protected] Contact Name: Ryan Woodford Contact Email: [email protected] FAACT’s mission is to educate, advocate and raise Elsevier is a world leader in medical publishing and awareness for all individuals and families affected by a provider of information solutions that enhance food allergies and life-threatening anaphylaxis. FAACT the performance of science, health and technology is also your voice for food allergy awareness. Whether professionals, empowering them to make better it’s keeping children safe at school, parents knowing decisions and deliver better care. their rights, responding to food allergy bullying, reading labels, dealing with workplace issues, traveling or dining out with the family, this website has the facts you need to manage food allergies and stay healthy. FAACT is here to support you in managing your food allergies – today, tomorrow and into the future.

LIVE RECORDED RECORDED+ 74 Exhibits

Fresenius Kabi USA LLC Three Corporate Drive Gold Partner Lake Zurich, IL 60047 Phone: (847) 550-5027 GlaxoSmithKline Website: www.fresenius-kabi.com/us Five Moore Dr Contact Name: Melissa Denton Research Triangle Park, NC 27709-3398 Contact Email: [email protected] Phone: (888) 825-5249 Fresenius Kabi is a global health care company that Website: www.gsk.com specializes in lifesaving medicines and technologies for Contact Name: Sudha Karthigeyan Contact Email: [email protected] infusion, transfusion and clinical nutrition. Our products are used to help care for critically and chronically ill Science-led global healthcare company with a patients. mission to help people do more, feel better, live longer. We research, manufacture and make available The people of Fresenius Kabi are driven by a common a broad range of medicines, vaccines and consumer purpose to put lifesaving medicines and technologies healthcare products. Visit our exhibit for information in the hands of people who care for patients and to find about our products and resources. answers to the challenges they face.

Gold Partner Grifols USA, LLC. 2410 Lillyvale Ave Genentech GUSA Los Angeles, CA 90032 1 DNA Way Phone: (323) 227-7630 South San Francisco, CA 94080 Website: www.grifols.com/en/home Phone: (650) 225-8230 Contact Name: Glorianna Bartolo Website: www.gene.com Contact Email: [email protected] Contact Name: Antony Rothwell Contact Email: [email protected] Grifols is a global healthcare company founded in Considered the founder of the industry, Genentech, Barcelona in 1909 committed to improving the health now a member of the Roche Group, has been and well-being of people around the world. Its four delivering on the promise of biotechnology for more divisions – Bioscience, Diagnostic, Hospital and Bio than 40 years. Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 Novartis Pharmaceuticals is dedicated to discovering, countries. developing, manufacturing and marketing prescription drugs that help meet our customers’ Pioneers in the plasma industry, Grifols operates a medical needs and improve their quality of life. growing network of donation centers worldwide. As a Please visit the Novartis exhibit where our sales recognized leader in transfusion medicine, Grifols also representatives will be available to discuss our offers a comprehensive portfolio of solutions designed products. to enhance safety from donation to transfusion.

LIVE RECORDED RECORDED+ 75 Exhibits

HollisterStier Allergy Kaz USA, Inc, A Helen of Troy Company 3525 North Regal St 400 Donald Lynch Blvd Spokane, WA 99207-5796 Marlborough, MA 01752 Phone: (800) 495-7437 Phone: (508) 490-7322 Website: www.hsallergy.com Website: www.helenoftroy.com Contact Name: Mary Miller Contact Name: Sonia LeBlanc Contact Email: [email protected] Contact Email: [email protected] Strength. Balance. Consistency. With nearly 100 Offering affordable, reliable, high quality HEPA filtration years of leadership in research, extract production products for over 25 years, Honeywell Air Purifiers and immunotherapy products, doctors around the are frequently recommended by allergists as part of a world choose HollisterStier Allergy. Our promise has patient’s overall treatment plan. always been to provide quality products, services and resources to physicians and allergy patients, and we Lincoln Diagnostics remain committed to those ideals today. Our complete PO Box 1128 line of high quality products – including phenol-free Decatur, IL 62525 extracts – and testing supplies, allows physicians to Phone: (217) 877-2531 Website: www.lincolndiagnostics.com provide patients with the best possible care. Allergy Contact Name: John Lenski Jr experts since 1921. Commitment since day one. Contact Email: [email protected] Lincoln Diagnostics is displaying state-of-the-art, safety- engineered skin testing devices that meet all current OSHA requirements. Our products include Multi-Test® Silver Partner PC (Pain Control), UniTest® PC (Pain Control), Multi-Test® II, Multi-Test®, Duotip-Test® II and Duotip-Test®. Please kaléo visit our exhibit to learn about the economic value 111 Virginia St of using Lincoln’s devices and why they are the most Suite 300 widely used and most extensively published-on devices Richmond, VA 23219 available. Website: www.kaleo.com Contact Name: Jennifer Norman Contact Email: [email protected] Med Learning Group kaléo is a pharmaceutical company dedicated to 450 7th Ave 32nd Floor building innovative solutions that can help empower New York, NY 10011 patients with certain serious, life-threatening medical Phone: (910) 612-3411 conditions and their caregivers. kaléo products Website: www.medlearninggroup.com combine established drugs with innovative delivery Contact Name: Connor Bishop Contact Email: [email protected] platforms, with the goal of achieving safety, efficacy and cost effectiveness. The mission of Med Learning Group is to design educational activities for healthcare practitioners that Please visit us at our virtual AUVI-Q booth for more increase competence, change behavior and optimize information. patient care. The focus of our education is to create innovative and interactive educational programs designed with scientific rigor, fair balance and evidence- based content.

LIVE RECORDED RECORDED+ 76 Exhibits

Nestlé Purina PetCare Company Gold Partner 1 Checkerboard Square 1C Merck & Co., Inc. Saint Louis, MO 63164 Phone: (314) 982-3363 2000 Galloping Hill Rd Website: www.purinainstitute.com Kenilworth, NJ 07033 Contact Name: Celia Suzuki Phone: (908) 740-4000 Contact Email: [email protected] Website: www.merck.com Contact Name: Nadine Curtin Nestlé Purina PetCare is one of the world’s leading For more than a century, Merck has been inventing pet food companies, dedicated to promoting the for life, bringing forward medicines and vaccines for bond between people and their pets. For over a many of the world’s most challenging diseases. Today, decade, Purina scientists have been investigating a Merck continues to be at the forefront of research to novel approach that can transform the management deliver innovative health solutions and advance the of cat allergies.The research has led to a discovery that prevention and treatment of diseases that threaten neutralizes the major cat allergen, Fel d 1, at its source people and animals around the world. For more in cats’ saliva before entering the environment. Pro Plan information, visit www.merck.com and connect with LiveClear, the first and only cat food proven to reduce us on Twitter, Facebook, Instagram, YouTube and allergens in cat hair, can be integrated into current care LinkedIn. pathways for cat allergies.

Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, NJ 07936-1080 ModuleMD, LLC Phone: (862) 223-1408 8359 Office Park Dr Website: www.novartis.com Grand Blanc, MI 48439 Contact Name: MaryBeth McAlister Phone: (248) 434-0444 Contact Email: [email protected] Website: www.modulemd.com Contact Name: Miranda Moore Novartis is reimagining medicine to improve and extend Contact Email: [email protected] people’s lives. As a leading global medicines company, we use innovative science and digital technologies ModuleMD enhances the clinical, operational and to create transformative treatments in areas of great financial performance of allergy practices. The medical need. In our quest to find new medicines, we ModuleMD WISE™ software suite streamlines practice consistently rank among the world’s top companies processes with an integrated ONC-Certified EHR, skin investing in research and development. Novartis testing, immunotherapy, practice management, revenue products reach more than 750 million people globally management, e-prescribe, telemedicine, appointment and we are finding innovative ways to expand access to reminder, parking lot check-in and patient engagement our latest treatments. About 105,000 people of more software. When you select ModuleMD WISE™ for your than 140 nationalities work at Novartis around the world. practice, you receive more than just a product or a Find out more at www.novartis.com. service; you have a dedicated partner with an interest in the success of your practice. In addition to technology, ModuleMD offers comprehensive billing and revenue management services. Providing solutions…not just software. Contact us for a demo today: [email protected]

LIVE RECORDED RECORDED+ 77 Exhibits

OptiNose, Inc. 1020 Stony Hill Rd Silver Partner Suite 300 Yardley, PA 19067 Pharming Healthcare, Inc. Phone: (267) 364-3500 Website: www.optinose.com 685 Route 202/206 Contact Name: Kristen Miller Suite 202 Contact Email: [email protected] Bridgewater, NJ 08807 Phone: (201) 675-0533 Optinose is a global specialty pharmaceutical company Website: www.pharming.com focused on serving the needs of patients cared for Contact Name: Lauren Arce by ear, nose and throat (ENT) and allergy specialists. Contact Email: [email protected] Optinose has offices in the U.S., the U.K. and Norway. To Pharming Healthcare, Inc. is dedicated to providing learn more, please visit www.optinose.com or follow us life-changing solutions to patients. Pharming is on Twitter and LinkedIn. currently involved in the marketing and development of drugs for the treatment of hereditary angioedema. Perrigo Company plc. 490 Eastern Ave Allegan, MI 49010 Phone: (434) 297-1148 Website: www.perrigopediatrics.com Diamond Partner Contact Name: Lindley Stakem Contact Email: [email protected] Sanofi Genzyme & Regeneron For over 20 years, Perrigo has been the trusted maker 777 Old Saw Mill River Rd of store brand infant formulas sold in the U.S., providing Tarrytown, NY 10591 high quality, complete infant nutrition that meets Phone: (914) 847-7000 required FDA standards at more affordable prices. To Website: www.regeneron.com / www.sanofigenzyme.com Contact Name: Medical Information learn more, explore our full product portfolio and find a Contact Email: [email protected] retailer near you, visit www.PerrigoPediatrics.com Regeneron Pharmaceuticals is a leading biotechnology company that invents life-transforming Gold Partner medicines for people with serious diseases. Sanofi is dedicated to supporting people through their Pfizer health challenges. We are a global biopharmaceutical company focused on human health. Since 2007, 235 East 42nd St New York, NY 10017 Sanofi & Regeneron have collaborated to develop & Phone: (610) 506-5496 commercialize fully human monoclonal antibodies Website: www.pfizer.com utilizing proprietary technologies. Contact Name: Gail Griffith Contact Email: [email protected] Pfizer Inc.: Breakthroughs that change patients’ lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

LIVE RECORDED RECORDED+ 78 Exhibits

SpoonfulOne 125 Willow Rd Gold Partner #200 Menlo Park, CA 94025 Takeda Phone: (919) 951-9480 300 Shire Way Website: www.spoonfulone.com Lexington, MA 02421 Contact Name: Jimmy Xu Phone: (781) 482-6579 Contact Email: [email protected] Website: www.takeda.com SpoonfulOne was developed by globally recognized Contact Name: Dawn Rafferty pediatric allergist, Dr. Kari Nadeau. SpoonfulOne is Contact Email: [email protected] a revolutionary, science-backed line of nutritional Takeda is a global, values-based, R&D-driven products for infants and toddlers that help stop a biopharmaceutical leader headquartered in Japan, childhood food allergy before it starts. Unlike other committed to bringing better health and a brighter products on the market that only cover peanut, milk or future to patients by translating science into highly- eggs, each serving includes safe, gentle amounts of innovative medicines. Takeda focuses its R&D efforts the 16 foods responsible for over 90% of food allergies. on four therapeutic areas: oncology, gastroenterology SpoonfulOne is powered by global landmark research (GI), neuroscience and rare diseases. We also and is backed by multiple proprietary studies. Learn make targeted R&D investments in plasma-derived more about SpoonfulOne at www.spoonfulone.com. therapies and vaccines. www.takeda.com

Stallergenes Greer 639 Nuway Circle NE Lenoir, NC 28645 Phone: (828) 759-7844 Silver Partner Website: www.stagrallergy.com Contact Name: William Mahoney Teva Pharmaceuticals Contact Email: [email protected] 400 Interpace Pkwy Headquartered in North Carolina, Stallergenes Greer’s Parsippany, NJ 07054 business in the United States is part of a leading Phone: (570) 294-7973 Website: www.tevausa.com global biopharmaceutical company specializing in Contact Name: Brian Eckley the development and commercialization of allergy Contact Email: [email protected] immunotherapy (AIT) products and services for use in Teva Pharmaceuticals is a global leader in generic the diagnosis and treatment of allergies. medicines and biopharmaceuticals. Building on more than a century-old legacy, Teva delivers high-quality products to patients in nearly every therapeutic area, has an established presence in generics, specialty, OTC and API, a fully integrated R&D function, strong operational base and global infrastructure and scale.

LIVE RECORDED RECORDED+ 79 Exhibits

The American Board of World Allergy Organization (WAO) Allergy & Immunology (ABAI) 555 E Wells St 1835 Market St Suite 1100 Suite 1210 Milwaukee, WI 53202 Philadelphia, PA 19103 Phone: (414) 276-1791 Phone: (215) 592-9466 Website: www.worldallergy.org Website: www.abai.org Contact Name: Angela Burant Contact Name: Gina Capozzoli Contact Email: [email protected] Contact Email: [email protected] The World Allergy Organization (WAO) is an The ABAI was established in 1971 as a conjoint board of international umbrella organization whose members the ABIM and ABP. The internal medicine subspecialty consist of 103 regional and national allergology and existed from 1936-1971 and the pediatric subspecialty clinical immunology societies from around the world. existed from 1944-1971. The ABAI is committed to By collaborating with member societies, WAO provides working closely with its parent boards to maintain direct educational outreach programs, symposia and the highest educational and clinical standards in the lectureships to members in nearly 100 countries around specialty of allergy/immunology. the globe.

Vitalograph, Inc. 13310 W 99th St Lenexa, KS 66215 Phone: (913) 730-3228 Website: www.vitalograph.com Contact Name: Mark Russell Contact Email: [email protected] Vitalograph is a global leader of respiratory diagnostics. Our products and services are chosen by medical professionals in healthcare, occupational health, telemedicine programs and for clinical trials. We manufacture and supply high quality, accurate and reliable spirometers and respiratory medical devices which aid the detection, diagnosis, and control of respiratory conditions. We have also delivered successful clinical trials for many of the world’s leading pharmaceutical companies, biotech, and contract research organizations. Visit our corporate website: www.vitalograph.com or call 1-800-255-6626.

LIVE RECORDED RECORDED+ 80 American College of Allergy, Asthma & Immunology Call for Session Proposals

2021 ANNUAL SCIENTIFIC MEETING

Promoting

PODIUM INNOVATION TO and PRACTICE DIVERSITY N O V. 4 – 8 ● NEW ORLEANS

The College is accepting proposals for Educational Sessions and Hands-On Workshops that echo the theme of the 2021 Annual Scientific Meeting, and: Reflect clinical innovation and cutting-edge research Convey best practices Present evidence-based medicine Stimulate discussion and challenge mindsets Deadline for submission is: December 6, 2020

college.acaai.org/21proposals

#ACAAI21 han you to the 2020 ACAAI Corporate Council Members

ENEATOR EERSI

ATRON EERSI